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ABSTRACT	  
The work presented in this thesis concerns a sub-family of the biologically important 
family of G-protein coupled receptors (GPCRs) known as histamine receptors. They 
are recognized as important drug targets for many disorders in mankind, such as 
allergic rhinitis and Alzheimer’s disease. 
This thesis has its roots in the first structure of histamine receptor H1, determined in 
complex with a first generation antihistamine (doxepin) in 2011. Here, extensive 
biological, computational and structural investigations have been carried out for H1 in 
complex with two second-generation antihistamines (cetirizine and fexofenadine). 
Crystal structures of H1-cetirizine (3.1 Å) and H1-fexofenadine (3.4 Å) show the 
binding modes of second-generation antihistamines correspond well with the previous 
docking studies. The so-called “anion binding site” on H1 is responsible for the high 
specificity of the ligands. Some regions on the receptor were difficult to define in the 
crystal structures. These regions were characterized by radioligand binding assays, 
together with molecular dynamic simulations (carried out by our collaborators from 
Oxford University) suggested that, second generation ligands have a significantly 
large impact on receptor dynamics. 
While H1 mediates many immune-related disorders, the histamine receptor H3 is a 
drug target to many mental disorders. In addition to the H1 work presented here, it is 
also reported the initial work done on the histamine receptor H3. With extensive 
screenings on various H3 constructs (from human and turkey organisms) and 
expression systems, it was observed that the best construct was from turkey. An 
optimal expression protocol in insect cells was obtained. This has established a secure 
starting point for future structural studies on H3. 
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1.1   Overview 
GPCRs are an extraordinary class of membrane proteins in several respects. Their 
importance is well justified by the interest they stimulate in both academic and 
pharmaceutical circles, especially in modern times. The seed of the present doctoral 
work was implanted in such a stimulating atmosphere, especially after the solution, in 
2011, of the first histamine receptor by So Iwata and co-workers (Shimamura et al., 
2011). This work spurred an excitement of possibilities, also extended to other types 
of histamine receptors. The H3 receptor is particularly interesting not only for the 
elucidation of mechanisms dealing with the transmission of signals in brain activity, 
but also as a potential drug target for mental diseases such as schizophrenia, and 
Alzheimer's disease. The present doctoral work aims to further the understanding of 
the ligand binding mechanism of H1 receptor. In using the experience accumulated 
from the study of H1, this thesis tries also to establish useful protocols to open the 
way to large-scale expression and production of H3 protein, thus preparing the 
framework for future purification and crystallization efforts. 
 
In this chapter, the field of membrane proteins, GPCRs and histamine receptors is 
briefly reviewed to provide the background for the following chapters. Also, since a 
very important part of this thesis centered on the use of crystallography to determine 
the structure of histamine receptor H1 with ligands, the main aspects of this discipline 
are also included. 
1.2   The cell membrane and membrane proteins 
Each cell in the human body has a plasma membrane surrounding its protoplasm.  
Overall, the plasma membrane is around 30Å thick (Wiener and White, 1992) and is 
formed by three major components: lipids, proteins and sugars. Its fluid lipid bilayer 
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is composed of phospho-lipids arranged with their polar hydrophilic heads facing 
towards the aqueous environment on each side whilst the non-polar hydrophobic tails 
form the inside of the bilayer. The cell membrane not only separates the cellular 
contents from the external surrounding environment as it is also involved in numerous 
complex functions.  While lipid molecules mainly provide structural support to the 
cell membrane, membrane proteins (MPs) are responsible for many important 
biological functions including cell signaling, cell adhesion, ion channel conductance 
and transport of molecules in and out of the cell.   Therefore, membrane proteins are 
of great importance making up 50% of the drug targets on the current market 
(Overington et al., 2006).   
 
Membrane proteins can be broadly grouped into two categories, peripheral membrane 
proteins and integral membrane proteins (IMPs) (Berg et al., 2007),depending on how 
they associate with the lipid bilayer. Peripheral membrane proteins are only associated 
with the surface of either side of the membrane, while integral membrane proteins 
(IMPs) are embedded in the membrane bilayer. IMPs can only be separated from the 
membrane through the disruption of their hydrophobic interactions with the lipids in 
the membrane, usually by the use of detergents or denaturing agents. IMPs can be 
further classified into two groups: integral polytopic proteins and integral monotopic 
proteins. Integral polytopic proteins have one or more transmembrane domains that 
span the membrane lipid bilayer, whereas integral monotopic proteins attach to  only  
one side of the membrane and do not cross it. (Blobel, 1980).  
 
IMPs are the most common type of membrane proteins and are responsible for many 
essential physiological functions. This thesis is focused on one of the most important 
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receptor families: G-protein coupled receptors (GPCRs). 
1.3   G protein-coupled receptors (GPCRs)  
GPCRs are integral membrane proteins that comprise one of the largest families of 
IMPs. More than 900 human GPCRs have been predicted to exist from analysis of the 
human genome (Fredriksson et al., 2003, Takeda et al., 2002). The seven-
transmembrane GPCRs play a critical role in regulating cellular responses to many 
types of biologically active stimuli with great prospects for medical and therapeutic 
interference (Zamanian et al., 2011, Takeda et al., 2002). Over 40% of the currently 
approved phamaceuticals, including many of the best selling drugs target GPCRs 
(Eglen et al., 2007). Consequently, GPCRs 3D structures are in demand since these 
structures could greatly assist in drug discovery processes (Insel et al., 2007). 
Nevertheless, structure solution of GPCRs to atomic resolution  has met with many 
tecnhical issues and crystal structures have only recently started becoming available. 
Presently, among the 900 potential human GPCRs only 15 structures are available 
(White, 2016). 
1.3.1   GPCR classification 
The first GPCR classification system was constructed by Kolakowski two decades 
ago, dividing GPCRs into 6 classes (A-F) based on sequence similarity; rhodopsin-
like (Class A), secretin-like (Class B), metabotropic glutamate receptors (Class C), 
fungal mating pheromone receptors (Class D), cAMP receptors (Class E) and 
frizzled/smoothened (Class F) (Kolakowski, 1994). Although this system is used most 
frequently, there are many disadvantages, including the fact that two of the classes 
cannot be found in mammals. A new human GPCR classification system, called 
GRAFS has been introduced and extensively used in the last ten years, GRAFS, 
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standing for Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin (Schioth 
and Fredriksson, 2005). Class A from the Kolakowski’s system and Rhodopsin family 
from the GRAFS system overlap extensively, with more than 85% of all GPCRs 
belonging to this class/family (Bjarnadottir et al., 2006). In this thesis, unless specially 
indicated, GPCRs will refer to members of the Rhodopsin family (Class A).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
1.3.2    Signal transduction mechanism of GPCRs  
Being a multi-functional protein family, GPCRs respond to a range of diverse ligands 
including light, neurotransmitters, biogenic amines, lipids, proteins, amino acids, 
hormones, odorants, nucleotides, chemokines, and many others (Kroeze et al., 2003). 
They react to extracellular stimuli by sending intracellular signals via an interaction of 
their intracellular domains with heterotrimeric G-proteins (Guanine nucleotide-
binding proteins). The general signal transduction pathway of GPCRs is shown in 
Figure 1.1. G-proteins have three subunits: Gα, Gβ and Gγ. In the inactive state, the 
G-protein α subunit is associated with the Gβγ complex and guanosine disphosphate 
(GDP), (Fig. 1.1A). When a GPCR is activated, the receptor undergoes a 
conformational change (Fig. 1.1B). This causes the receptor to act as a guanine 
nucleotide exchange factor, resulting in the exchange of GDP with guanosine 
triphophate (GTP) in the G-protein α subunit (Fig. 1.1C). After the GTP replaces 
GDP, the G-protein is activated, resulting in the dissociation of the α subunit and βγ 
complex as well as from the receptor (Fig. 1.1D). As a consequence, both the α 
subunit and the βγ complex are activated to bind and regulate the activities of their 
downstream target proteins, passing the signal to different types of second messengers 
such as cAMP. Following this, the α subunit hydrolyzes the GTP to GDP, and 
rendering the α subunit inactive (Fig. 1.1E), allowing it to bind to the βγ complex 
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(Fig. 1.1A) and terminating thus the downstream signaling events (Pierce et al., 
2002). 
 
The diversity in the downstream signaling systems of the G-proteins and the multiple 
functions of GPCRs can be illustrated by the various types of G-proteins. The three 
subunits (Gα, Gβ and Gγ) of a G-protein can be divided into a variety of families. The 
α-subunits, which establish the fundamental properties of a G protein, have four 
families: Gαs, Gαi/o, Gαq/11 and Gα12/13, and members from each family share some 
similar functional properties. The Gβ and Gγ subunits exist as a βγ-complex, which is 
Figure 1.1 Schematic of the general signal transduction mechanism of a GPCR. A: Inactive state 
of GPCR and G-protein. B: An agonist binds to the receptor. C: The receptor is activated, GDP is 
replaced by GTP. D: G-protein α subunit and Gβγ complex dissociated and both components are 
activated. E: GTP hydrolyzed to GDP. Adapted from (Pierce et al., 2002) 
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combined from 5 types of Gβ subunits and 12 types of Gγ subunits (Hermans, 2003). 
The G-proteins anchor to the intracellular membrane by both the α-subunit and the γ-
subunit through their covalently attached lipid tails (Bohm et al., 1997). 
1.3.3    GPCR functional states and ligand types 
The binding of ligands to the GPCR do not necessarily activate the protein. Different 
types of ligands cause diverse effects as shown in Figure 1.2. Agonists are ligands that 
trigger a biological response once it binds to the receptor. Partial and weak agonists 
refers to ligands that only trigger a partial or very weak intracellular response, while 
full agonists trigger a full response. Inverse agonists are ligands that hinder the 
receptor’s constitutive activity once it binds to the receptor by stabilizing the 
interactions that keep the receptor in its inactive conformation. A neutral antagonist is 
a ligand that binds to the receptor without changing the activation state. Inverse 
agonists, partial agonists or neutral antagonists, which block the binding sites to 
prevent agonists from binding, are collectively known as antagonists (Tate, 2012).  
Agonists binding to a GPCR are not always necessary for interaction with the G-
protein as many GPCRs showing constitutive activity (Kudo et al., 1996).  
 
	  Figure 1.2 GPCR biological response level with the presence of 
different types of ligands. Adapted from (Tate, 2012). 
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1.3.4    GPCR structural scaffolds 
There are currently a number of GPCR structures solved, most with antagonist bound. 
The currently available GPCR structures have revealed that GPCRs share very similar 
structures in the transmembrane domain, but vary notably in their N- terminus, C- 
terminus and loops. The common scaffold of GPCRs is explained in Figure 1.3 using 
the histamine receptor H1 as a representative example. All GPCRs have a well-
conserved seven-transmembrane helix domain across the cellular membrane, where 
each helix is composed of about twenty-five to thirty-five residues with a high degree 
of hydrophobicity (Kroeze et al., 2003). These helices are connected by three 
extracellular loops and three intracellular loops. Within the transmembrane helical 
bundle, there is a conserved interaction system built up by 24 non-covalent inter-
helical contacts (Venkatakrishnan et al., 2013). This network is conserved among 36 
spatial positions occupied by various residues from different receptors as shown in 
Figure 1.4. GPCRs also have an extracellular N-terminus and an intracellular C-
terminus with variations in function and length. 
In Figure 1.3, several shared details of GPCRs are emphasized, including common 
sequence motifs, many of which are involved in structural stabilization. The most 
conserved motifs are the DR(E)Y, CWxP and NPxxY in helices III, VI and VII, 
respectively. A disulphide bond formed between two cysteines in extracellular loop 2 
(ECL2) and helix III is also conserved. These highly conserved features play 
important roles in GPCR activation and signal transduction. Some of the interactions 
between these motifs are referred to as micro molecular switches, including the so-
called the ionic lock, the rotamer toggle and the 3-7 lock, all of which are involved in 
receptor activation (Nygaard et al., 2009, Trzaskowski et al., 2012, Schwartz et al., 
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2006). The ionic lock involves the DRY motif on helix III and the D/E residue on 
helix VI. It stabilizes the receptor via interactions between the two helices 
(Trzaskowski et al., 2012). The rotamer toggle switch, involving the CWxP motif on 
helix VI with the aromatic residues Cys, Trp and Pro, modulate the domain around the 
Pro residue, causing the interacting ligand and its receptor to undergo conformational 
changes (Bhattacharya et al., 2008). The 3-7 lock, consisting of variable residues in 
different receptors, is a switch which involves interaction between a pair of residues 
in TM3 and in TM7 that contributes to the activation of several GPCRs, including the 
Histamine receptor H1 (Shimamura et al., 2011). The so called “structural hub” helix 
III has another unique feature, a tilt-angle, which is around 35° to the axis 
perpendicular to the plane of the lipid bilayer (Venkatakrishnan et al., 2013). It has 
interactions with the bound ligand, ECL2, ICL2, G-protein and most of the 
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transmembrane helices. These intense interactions prove its important role in 
maintaining the structure and function.  
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Figure 1.3 Conserved GPCR features. Structure of Histamine receptor H1 (PBD: 3RZE) as a 
template of GPCRs, conserved motif D(E)RY, CWxP and NPxxY are colored in orange, pink 
and yellow respectively; two Cystines and the disulfide bond between them are colored in blue. 
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A number of conserved spatial positions within the ligand binding pocket are 
observed in nearly all GPCRs. Equivalent residues at these positions from different 
receptors make contact with the ligands in nearly all class A GPCRs, regardless of 
residue types. These conserved positions include 3.32, 3.33, 3.36 on helix III, 6.48 
and 6.51 on helix VI and 7.39 on helix VII (Venkatakrishnan et al., 2013). Spatial 
position numbers refer to the GPCR Ballesteros–Weinstein numbering system 
(Ballesteros and Weinstein, 1995). Within GPCR subfamilies, different receptors also 
share several conserved positions around the ligand-binding pocket. This feature is 
explained below by using the aminergic GPCR subfamily as a representative 
Figure 1.4 Conserved inter-helical contact positions of GPCR. Using the structure of Histamine 
receptor H1 (PBD: 3RZE) as a representative template of GPCRs. The 36 inter-helical contacts 
related positions are coloured in salmon, 16 ligand contact related positions of aminergic GPCRs 
are coloured in green, positions responsible for both helical and ligand contact are coloured in 
purple. The 6 conserved ligand contact positions across all GPCRs: 3.32, 3.33, 3.36, 6.48, 6.51 and 
7.39 are marked with Ballesteros–Weinstein numbers. 
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template. Comparing the structures of the six receptors: β1 AR (Warne et al., 2012), 
β2 AR (Wacker et al., 2010), D3R (Chien et al., 2010), H1 M2R (Haga et al., 2012) 
and M3R (Kruse et al., 2012), there are 10 spatial positions that have a high 
probability to be involved in ligand binding events. Equivalent residues at each of 
these positions have non-covalent contacts with the ligands and are present in more 
than half of different types of receptors. These positions include 3.28, 3.37, 5.39, 5.42, 
5.43, 5.46, 6.52, 6.55, 7.35 and 7.43. Therefore, together with the other six class A 
GPCRs conserved positions, there are 16 identical ligand binding related positions in 
aminergic GPCRs (Fig 1.4). 
 
In 2011, the structure of a GPCR in complex with the G-protein was solved. The 
structure of the β2AR ternary complex with an agonist and a G protein was elucidated 
for the first time, which presented the non-rhodopsin GPCR transmembrane signaling 
of a G-protein at the structural level (Rasmussen et al., 2011). The active state of 
β2AR is stabilized by extensive interactions with the G protein, with the interface 
between β2AR and the G protein formed by ICL2, helix V and helix VI (Fig. 1.5a) of 
the GPCR. The main transmembrane conformational changes of β2AR from the 
inactive to the active state include a 14Å outward movement of helix VI on the 
Figure 1.5 Interactions between the β2AR receptor and G protein. β2AR is coloured in green, 
and G protein is coloured in golden (Rasmussen et al., 2011). 
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intracellular side and an intracellular extension of helix V by 7 residues.  Together, 
the structural changes on helix V and helix VI lead to the formation of a binding 
cavity for the G protein. The majority of the sequences involved in G protein coupling 
are not conserved among GPCRs, possibly due to the diversity of G protein types. 
Interactions between the G protein and the conserved DRY motif in helix III, and 
between the DRY motif and the NPxxY motif (helix VII) have both been observed 
(Fig. 1.5a). The structure also suggests that the receptor residues Thr 68 and Asp 130 
interact with Tyr 141 on ICL2 dragging Phe 139 into the hydrophobic G protein 
binding pocket (Fig. 1.5c), highlighting the important role of DRY motif in receptor-
G protein interaction.  
1.3.5    Challenges and strategies in GPCR structural studies  
X-ray crystal analysis is the modern preferred technique to analyse proteins structural 
details. High-resolution data for GPCRs can be obtained only when enough pure and 
stable protein for the necessary formation of crystals is produced. Even after years of 
research and effort, major challenges in the expression, purification, and 
crystallization of proteins exist in obtaining well-ordered crystals. Several strategies 
and tools have been developed and used for GPCR structural studies. These have 
accelerated determination of GPCR crystal structures in recent years. 
1.3.5.1  Expression systems  
It is important to choose a heterologous expression system that can produce a 
sufficient yield of monodispersed protein, a prerequisite for structural analysis.  The 
E.coli expression system has many advantages for protein expression, such as low 
cost and rapid cell growth rates. However, the difference in lipid composition of the 
E.coli membranes compared to eukaryotic cell membranes, can potentially affect the 
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protein folding state. Consequently, most GPCR structural studies were carried out in 
insect cells (Tate and Grisshammer, 1996). The advantage of this system is the high 
yield of homogenous GPCRs suitable for crystallization. However, there are still 
some drawbacks, such as long growth time and requirement of special equipment and 
laboratory setup. The work of Asada and Uemura suggested that Pichia Pastoris is a 
suitable alternative host for GPCRs expression, comparable to the insect cells system 
(Asada et al., 2011), with the structures of H1 (Shimamura et al., 2011) and A2a 
(Hino et al., 2012) solved using protein produced from the Pichia expression system. 
Pichia Pastoris cells can be grown in flasks or in bioreactors. The flask system is 
flexible and several different expression conditions can be carried out in parallel for 
the purpose of expression condition screening.  The bioreactor system, however, often 
results in a greater protein yield since the cells can be grown to a much higher density 
(Singh et al., 2008).  Mammalian cells provide an environment most similar to the 
native membranes containing eukaryotic proteins, increasing the likelihood of 
expression of functional GPCRs. Despite this, it is difficult and time consuming to 
maintain healthy cell lines in culture, which is critical for high protein expression 
levels (Andrell and Tate, 2013). 
1.3.5.2   Inherent structural flexibility and instability 
Another obstacle to obtaining structural information is the inherent structural 
flexibility and instability of GPCRs. This is probably the biggest obstacle that needs 
to be overcome. The inherent flexibility needed to adopt different conformations of 
the active and inactive states of GPCRs make these receptors intrinsically dynamic, 
and it is the cause of their instability. GPCRs also have reduced hydrophilic areas, 
these typically play an important role in the formation of crystal contacts, which in 
turn result in the production of diffraction-quality crystals. 
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Protein engineering of the non-rhodopsin GPCRs has involved a series of approaches 
to obtain more stable constructs, including N- an C- termini truncation, point 
mutations and third intracellular loop (ICL3) replacement (Chun et al., 2012). The 
ICL3 in GPCRs is poorly structured and its flexibility causes undesired movements to 
the transmembrane helix V and VI, which is proposed to make the crystallization 
difficult. Different strategies have been used to tackle this problem, including fusion 
body, antibody complexes and mutagenesis to increase thermostability.  
 
In 2007, Cherezov and his co-workers replaced the ICL3 of the β2 adrenergic receptor 
(β2AR) with T4 lysozyme (T4L), the T4L stabilized flexible helix V and helix VI, 
yielding a 2.4 Å resolution structure of the fusion protein (Cherezov et al., 2007). 
Since then, there have been 17 GPCR structures solved by the T4L engineering 
method, and T4 lysozyme-engineering has become the most successful method to 
date. More recently, the thermostabilized apocytochrome b562 RIL (BRIL) was also 
used as fusion partner in opioid nociceptin/orphanin FQ peptide receptor.  The 
structure, which previously would not crystallize with the T4L insertion (Thompson et 
al., 2012), was determined at 3.0 Å resolution (Chun et al., 2012), suggesting BRIL is 
a valid alternative fusion partner for crystallization of GPCRs. In 2014, two modified 
versions of the T4L fusion body, dsT4L (disulfide-stabilized T4L) and mT4L 
(minimal T4L), have been introduced and T4L could be applied even more broadly. 
The fusion strategy is useful for enlarging the hydrophilic region of the receptor and 
to avoid the flexibility of the ICL3 domain. However, to stabilize the trans-membrane 
region, the receptor always has to combine with the high-affinity inverse agonists to 
reduce the conformational changes associated with its basal activity (Tate 2012). The 
disadvantage of this strategy is that the ICL3 is located at the site where the G-protein 
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couples, blocking the insertion of a potential fusion partner at ICL3. Therefore, this 
strategy cannot be used to reveal the G-protein binding stage of GPCRs (Chun et al., 
2012). Another strategy of using T4L is to insert T4L in the N-terminus instead of in 
ICL3. This strategy has enabled the successful determination of the structure of 
human β2AR bonded to a G protein (Rasmussen et al., 2011).  
 
The strategy of thermostabilization by mutagenesis is well established and has been 
proven quite successful (Tate, 2012). By using mutagenesis, no fusion partner is 
needed. The receptor amino acids sequence can be modified to improve 
thermostability and tolerance to short-chain detergents, eventually, to facilitate crystal 
formation. However, this is both a time consuming and costly process.  
1.3.5.3  Crystallization  
Membrane proteins in their native state are embedded in a lipid bilayer, from which 
they are solubilized by the addition of detergents. The traditional aqueous-based 
crystallization methods (such as vapor diffusion) mixes the protein with various 
crystallization solutions, leaving it exposed to the precipitant solution, with risk of 
denaturation and aggregation. The solution conditions would be even more difficult 
for unstable proteins like GPCRs. It has been observed that Lipidic Cubic Phase 
(LCP) has been the most successful crystallization method for GPCRs during recent 
years.  In this method a protein-detergent-complex (PDC) is transferred into a 
lipid matrix that helps the stabilization of the protein. This crystallization method 
leads to type I crystal packing where protein molecules make contacts via both 
hydrophobic and hydrophilic regions (Landau and Rosenbusch, 1996).  
1.3.6   Structure-based drug discovery (SBDD) and GPCRs 
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As one of the most important drug target protein family, GPCRs draw a lot of interest 
in both industry and academic research. Especially in the last decade, extensive 
research has involved identification of GPCR subtypes, cloning, establishment of 
expression cell lines, GPCR polymorphisms and others. In spite of these efforts, for a 
long time, only a limited number of crystal structures have been available. Hence, 
drug discovery programs have been limited to functional information using tissue-
based assays and high throughput screening (HTS).  In the last few years, the 
increasing numbers of reported GPCR structures have made an enormous impact in 
the field of GPCR drug discovery. 
1.3.6.1  Structure-based drug discovery (SBDD) 
Structure-based drug discovery (SBDD) is a strategy using the three-dimensional 
atomic structure of a protein or a ligand-protein complex to obtain information 
regarding the mode of ligand binding. Design of a new potential drug is then based on 
this information (Blundell, 1996). There are many examples of successful drugs that 
were designed based on their target protein 3-D structures. The early examples of 
SBDD include proteases and kinases, of which the most successful example is the 
development of HIV (human immunodeficiency virus) protease inhibitors (Wlodawer 
and Vondrasek, 1998). The HIV protease was identified as a potential anti HIV drug 
due to its critical role in the HIV life cycle, where it is responsible for the HIV viron 
maturation by correctly cleaving its polypeptide precursors. The HIV protease 
inhibitors leave the HIV polyproteins in their immature non-infectious form. The 
structure of the HIV protease started to appear around the end of 20th century, 
followed by the development of a range of HIV protease inhibitors, including 
Saquinavir, Ritonavir and Indinavir, all using structural-based drug design strategies 
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(Lv et al., 2015).  
1.3.6.2  SBDD for GPCRs 
Although SBDD had been successfully applied to soluble proteins, the application of 
the method to GPCRs only started around the year 2000 with bovine rhodopsin as the 
first ever GPCR structure solved (Palczewski et al., 2000). Subsequently, the use of 
the method accelerated after 2007, when other GPCR crystal structures started to be 
solved at an increasing pace. Currently, there are 22 unique GPCR structures solved 
across all major classes of GPCRs including A, B, C and F (White). This success is 
due to the application of several methods of crystallization described earlier. The 
availability of these structures may be assumed to be of equal value to GPCRs drug 
discovery similar to the structures of soluble proteins. 
 
There are two main strategies for structure-based drug discovery: (1) discovery of 
new drug series using structure-based virtual screening and  (2) optimization of lead 
candidates guided by the 3D structure. Structure-based virtual screening is aided by 
docking techniques, which uses a structurally defined ligand-binding site (with or 
without a ligand) of a target protein to screen a large number of compounds. 
Information such as shape of the binding site, protein ligand favorable interactions, 
together with the properties of new ligands could help to find the HIT compounds for 
further screening. Orthosteric binding sites of GPCRs are particularly suitable for 
virtual screening. These are deeply buried in the protein when compared with most of 
the exposed and large binding sites of soluble proteins. This characteristic allows the 
binding sites in GPCRs fit small molecules with high efficiency. On the top of that, 
the large number of GPCR ligands in the library is ready to use, also contributed to 
the success. 
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With more GPCR structures being solved at a convenient resolution, i.e. better than 3 
Å, SBDD of GPCRs will be very helpful in lead optimization.  Hopefully, the 
structure of protein-ligand complexes will provide information on shape, orientation 
of the ligand and their favorable interactions. This will help medicinal chemists to 
identify the most suitable areas of the ligands for optimization in terms of solubility 
and selectivity while maintaining the binding affinity the ligands.  Fragment screening 
is a another frequently applied method for many pharmaceutical companies (Chessari 
and Woodhead, 2009). However, the disadvantage of this method is the high hit rate, 
resulting in a heavy downstream workload in verifying the hits.  
1.4   Histamine receptors 
Histamine is an effective biogenic substance that induces various physiological effects 
(Axe et al., 2006). Its tight connection to brain function is related to the histamine 
released by the neurons and projected to all the major regions of the brain (Brown et 
al., 2001). The actions of histamine are launched by activating histamine receptors as 
they have histamine as their natural agonist. To date, four histamine receptors have 
been discovered, including H1, H2, H3, and H4, which all transduce extracellular 
signals through different types of G-proteins, namely Gq/11, Gs, Gi/o and Gi/o 
respectively (Parsons and Ganellin, 2006). The four histamine receptors demonstrate 
the diverse biologic effects of histamines. H1 regulates severe allergic responses, H2 
triggers the secretion of gastric acid, H3 is important for regulation of 
neurotransmission and H4 mediates immunological reactions (Leurs et al., 2005) (Axe 
et al., 2006).  
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Sequence alignment of the four histamine receptors is shown in Figure 1.6 and table 
1.1. Within the trans-membrane region (excluding N-terminus, C-terminus and 
intercellular loop 3) the sequence identity between H3 and H4 is 50%, while between 
any other pair of histamine receptors, it is only around 30%. As shown in table 1.1, all 
the receptors have similar structural scaffolds within the transmembrane region, play 
an important role in GPCR activation and signal transduction. Within the 16 
aminergic GPCR ligand contact related positions, H3 and H4 share up to 81% 
identity. 
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Figure 1.6 Sequence alignment of 4 histamine receptors. The alignment of human H1, H2, H3 
and H4 amino acid sequences (N-terminus, C-terminus and intercellular loop 3 excluded). The 36 
topologically conserved positions responsible for non-covalent inter-helical contacts are marker 
with red dots, while the 16 aminergic GPCR ligand-binding related positions are marked with 
green dots. All the positions are shown as columns in black box. Equivalent residues in the boxes 
are coloured according to the percentage of identical residues in each column, the darker, the more 
identical residues. The most conserved residues of each helix are denoted using Ballestero-
Weinstein numbering system. 	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Table 1.1 Four histamine receptors sequence similarity in different regions. Identical 
sequences ≥ 50% are marked in shade. 
	  
 
 
 
 
 
 
	  
	  
 
 
 
 
 
 
 
 
 
Sequence 
1 
Sequence 
2 
Identical sequences (%) 
Transmembrane 
region 
Conserved inter-helical 
contact positions 
Conserved ligand 
contact positions 
H1 H2 33.0 58% 44% 
H1 H4 28.0 44% 44% 
H1 H3 30.0 47% 38% 
H2 H4 25.0 56% 31% 
H3 H2 27.0 53% 31% 
H3 H4 50.0 72% 81% 
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1.4.1   Human histamine H1 receptor (H1) 
As one of the most well characterized drug targets, H1 receptor’s antagonists are very 
important in controlling a variety of diseases, especially allergic reactions 
(Overington et al., 2006). Activated H1 binds to G-protein subfamily Gq/11 which 
stimulates phospholipase C, leading to the hydrolysis of phophatidylinositol 4,5-
bisphosphate (PIP2), formation of inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 causes calcium mobilization and DAG activates of Protein 
Kinase C (PKC) (Noubade et al., 2007). H1 also regulates other signaling pathways, 
but there is currently limited information regarding the cell type-specific signaling 
pathways (Noubade et al., 2007). 
 
First-generation drugs, however were known to deliver unwanted side effects, 
including dry mouth, sedation and arrhythmia (Shimamura et al., 2011). Although the 
x-ray structure of H1 in complex with doxepin has revealed some of the H1 specific 
ligand binding related residues (Shimamura et al., 2011), GPCRs can accommodate 
diverse ligands within their binding site in general. Different ligand complexes may 
possibly present different and more specific binding pocket information. Indeed, more 
detailed structural information will facilitate new-generation antagonist design, which 
keeps H1 receptor selectivity while avoiding or reducing the side effects.  
 
The H1 structure shares some common motifs with other GPCRs, such as D(E)RY, 
CWxP and NPxxY and the disulphide bond between Cys 180 in loop 2 and Cys 100 
at the extracellular side of helix III (Shimamura et al., 2011). The seven residues 
between the disulphide bridge and helix V in ECL2 play an important role, positioned 
at the entrance of the ligand-binding pocket (Fig. 1.7a). A special property of H1 is 
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that it contains a seven-residue region that is a only few amino acids longer than other 
GPCRs, forming a larger space within the ligand-binding pocket, potentially fitting 
larger H1 antagonists (Shimamura et al., 2011). A second special feature of H1 is a 
conserved Pro 161 which induces a kink in helix VI leading to a tight i+3 helical turn, 
which can accommodate the relatively large Trp side chain, an important feature for 
ligand specificity of H1 (Shimamura et al., 2011). 
 
The ligand-binding pocket of H1 was characterized via the first-generation H1-
antagonist Doxepin (Shimamura et al., 2011). To date, the H1 ligand binding pocket 
is the deepest from all the known GPCR structures (Venkatakrishnan et al., 2013). It 
was found that some residues that are common among aminergic receptors constitute 
the main part of the H1 binding pocket. One signature feature of the H1 binding 
pocket is an anion-binding site, located at the entrance of the ligand binding region. 
This is constituted by Tyr 431, His 450, Lys 179 and Lys 191 (Fig. 1.7b). A 
phosphate ion observed in the H1 structure has played a positive role in assisting 
ligand binding siting in this anion-binding site (Shimamura et al., 2011) (Fig. 1.7). 
 
It has been shown that H1 antagonists work as inverse agonists on the receptor, 
thereby weakening its basal activity. The H1-antagonist doxepin makes hydrophobic 
interactions with the indole ring of Trp 428, potentially stabilizing the hydrophobic 
packing around helix VI (Shimamura et al., 2011). 
 
An important contraction of the extracellular ligand-binding pocket has been found in 
the β2-AR. This is believed to be involved in GPCR activation. With the exception of 
H1, the antagonists are all much larger than the natural agonist histamine, and the size 
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enables them to block the activation-related contraction because it is a twisting motion 
(Shimamura et al., 2011) 
	  
Figure 1.7 Structural key features of H1, viewed from the extracellular side. Seven residues 
between the disulphide bridge and the helix V in ECL2 are colored in red. (b) Anion-binding site 
composed of Tyr 431, His 450, Lys 179 and Lys 191, shown as sticks in green colour, a phosphate ion 
is bind in it, shown in orange.  
 
The crystal structure of H1 with doxepin has revealed information about its binding 
pocket, as well as raised questions about specific features of the H1 ligand-binding 
pocket. Doxepin also can bind to H2 and the Muscarinic receptor with different 
affinities (Figueiredo et al., 1990). A comparison of the ligand contacts in related 
positions of Histamine receptors are compared to other aminergic GPCRs (Fig. 1.8) 
shows five best similarities are found, as listed in Table 1.2. H1 and the muscarinic 
receptor share 56% of their sequences, while H1 and H2 share 44% of them. More  
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natural agonist histamine, and the size enables them to block the activation-related 
contraction because it is a twisting motion (Shimamura et al., 2011) 
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Figure 7. Structural key features of H1R, viewed from the extracellular side.  
(a) Seven residues between the disulphide bridge and the TM 5 in ECL2 are colored in red. (b) Anion-
binding site composed of Tyr 431, His 450, Lys 179 and Lys 191, shown as sticks in green colour, a 
phosphate ion is bind in it, shown in orange.  
(Generated by PyMOL) 
 
 
 
The H1 crystal structure with doxepin has revealed some information of its binding 
pocket, and also raised questions about specific features of H1 ligand binding pocket, 
while doxepin also can bind to H2 and Muscarinic receptor with different affinities 
(Figueiredo et al., 1990). Compare the ligand contacts related positions of Histamine 
receptors with other aminergic GPCRs (Fig. 8), the 5 best similarities are listed in 
table 2. H1 and muscarinic receptors share 56% identical sequences, while H1 and H2 
share 44% of identical sequences. More detailed interactions within the binding 
pocket are needed.  
TM!V!
ECL!3!
Lys!191!
His!450!
!
Lys!179!!
Tyr!431!
! !
Sequence 1 Sequence 2 Identical 
residues (%) 
H3 H4 81 
H1 Muscarinic2 R 56 
H1 Muscarinic3 R 56 
H1 H2 44 
H1 H4 44 
10
Beta2-AR
Beta1-AR
Dopamine-R
Muscarinic2-R
Muscarinic3-R
H1
H2
H3
H4
W D V V T A S S SW F FN Y N Y
W D V V T A S S SW F FN FN Y
FD V C T V S S SW F FH Y T Y
W D Y SN T T A AW Y N VW Y Y
W D Y SN T T A AW Y N VW Y Y
W D Y ST K T A NW Y F FH IY
Y D V C T G D G TW Y F FE LY
W D Y C T LA SEW Y TM Y FW
W D Y C T LT SEW Y ST Y FW
Conservation
Quality
Consensus
9 *6 6 + 3 5 8 4 *9 5 3 4 5 +
                
W D Y C T + T S SW Y F+ Y + Y
Figure 1.8 Alignment of residues at the 16 
ligand-bindi g related positions of aminergic 
GPCRs. Equivalent residues are coloured 
according to the percentage of identical 
residues. 
Table 1.2 Sequence similarity within the 
16 ligand-binding related positions of 
aminergic GPCRs.  
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detailed interactions within the binding pocket are clearly needed.  
1.4.1.1  Antihistamines 
Antihistamines are widely used medications for the treatment of allergic rhinitis, 
allergic conjuctitivities, urticaria, coughs, colds and insomnia (Church et al., 2010). 
They are capable of down-regulating the H1 histamine-activated reactions on the 
endothelial cells, the airway smooth muscle and some nerve fibers. This helps to 
diminish the vascular permeability, with reduced release of fluid and improved 
peripheral resistance, bronchodilation and ease the mucosal and cutaneous itching. 
(Simons, 2003) 
 
The current antihistamines on the market could be classified into two groups: classic 
antihistamines (also called first-generation antihistamines or sedating antihistamines) 
and non-classic antihistamines (also called second-generation antihistamines or 
nonsedating antihistamines), depending on whether or not they have an effect on the 
central nervous system (CNS). 
 
Classic antihistamines generally have small molecular weight and are highly 
lipophilic, like in the case of diphenhydramine and hydroxyzine. They are able to 
cross blood brain barrier (BBB) and affect the CNS, thereby causing sedation. 
The non-classic antihistamines, such as terfenadine, astemizole, loratadine, cetirizine, 
azelastine and fexofenadine, on the other hand, are not lipophilic and cross the BBB 
to a minimal degree, rarely creating sedation. 
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1.4.1.1.1   Classic antihistamines 
The classic antihistamines efficiently relieve allergic symptoms, emerged on the 
market in the 1940s-1950s (Emanuel, 1999). Unfortunately, they were also quite toxic 
in many ways. Firstly, they were well-known sedative antihistamines. This class of 
drugs can go across BBB and disrupt the histamine-regulated neurotransmission at 
CNS, which can cause sedation, drowsiness and fatigue, resulting in much diminished 
cognitive function such as learning performance and the ability to safely operate 
machinery. (Church et al., 2010) As well as from the sedation side effect, classic 
antihistamines also have anti-cholinergic side effects. The initial antihistamines share 
the basic chemical structure with other types of medications, such as cholinergic 
muscarinic antagonists, neuroleptics and antihypertensive drugs (Church et al., 2010, 
Emanuel, 1999). Moreover, H1 also has high sequence similarity with other aminergic 
receptors, having muscarinic receptors as the highest, with around 45% sequence 
identity (Simons and Simons, 2008). Therefore, this class of antihistamines has non-
specific selectivity, interacting with e.g. the muscarinic receptor, the adrenergic 
receptor, the dopamine receptor, etc. (Church et al., 2010, Emanuel, 1999), causing 
undesirable side effects such as dry mouth, tachycardia and urinary retention 
(Bousquet et al., 2001). 
1.4.1.1.2   Non-classic antihistamines 
Since the 1980s, a new generation of antihistamines has been developed via structural 
modification of existing drugs (Simons and Simons, 2008).  Compared to the old 
drugs, they have better selectivity and rarely cross the BBB because of their larger 
molecular weight and reduced lipophilicity. Hence, the related side effects have been 
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generally overcome. 
 
Nevertheless, other side effects have emerged among some of these agents, especially 
the cardiotoxic effects. In 1986, it was reported that an overdose of terfenadine or 
astemizole could lead to ventricular arrhythmia, namely torsades de pointes (TdP). 
These antihistamines work as a blocker to certain type of potassium channel, which 
mediates the ventricular repolarization, and results in a prolongation of the QT 
interval leading to for example ventricular arrhythmias (Camelo-Nunes, 2006). 
However, the cardiotoxic effects are not class specific. There are other agents, such as 
loratadine, cetirizine, azelastine, and fexofenadine that are free from torsades de 
pointes or other ventricular arrhythmias. (DuBuske, 1999) 
1.4.1.1.3   Cetirizine 
As an example, cetirizine is a widely used non-classic antihistamine, with the trade 
names such as Zyrtec and Reactine. The compound is the carboxylated metabolite of 
hydroxyzine, and consists of a diphenylmethane moiety directly connected to a 
peperazine moiety and an alkyl group with a carboxyl group as shown in Figure 1.9. 
Hydroxyzine has an alcohol in place of the carboxyl group of cetirizine.  
Figure 1.9 Cetirizine and Hydroxyzine 
	   39	  
1.4.1.1.3.1   Sedating or non-sedating antihistamines 
When we talk about the non-sedative effect of second-generation antihistamines, the 
concept of brain penetration has to be mentioned, which is the direct reason of 
sedation.  
 
To determine the ability of brain penetration of a compound, Overton and Meyer’s 
theory was applied early in the 20th century. According to this theory, the compound 
with a higher level of lipophilicity can go through the blood-brain barrier more easily. 
However, this rule has proved to be too simple, as more parameters need to be taken 
into account. For instance, the level of ionization of a compound at physiological pH 
should also be considered because only the neutral species of the compounds pass 
across the BBB.  Another very important parameter is the hydrogen bonding capacity. 
A higher hydrogen bonding capacity means that a larger portion of the compound can 
bind to the serum protein before reaching the BBB, bringing down the level of brain 
penetration. The last factor is the P-glycoprotein, which plays an important role as 
active transporter. All the parameters should be considered together for the final 
assessment of the level of brain penetration. 
 
Furthermore, molecular weight is also a key parameter to consider, large molecules 
have difficulties with going through the BBB. However, this argument is only valid to 
a certain level because the effect of size can be negligible when the molecular weight 
is below 500 Da. 
 
Compared to the first generation antihistamines, cetirizine has a relatively low 
lipophilicity (100-fold lower than hydroxyzine) and a large hydrogen bond capacity. 
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At physiological pH, cetirizine is mainly in the zwitterionic form. All these 
physicochemical properties together with its high efflux rate render cetirizine non-
sedative. 
1.4.1.1.3.2   Selectivity 
Both cetirizine and hydroxyzine are very potent, even though cetirizine has a 3-fold 
lower affinity. When it comes to selectivity, though, cetirizine is superior over other 
receptors (serotonin receptor, a1-adrenergic receptor and D2 dopamine receptor), 
while hydroxyzine is weak in selectivity. Without a structure of H1-cetirizine 
complex at atomic level, the detailed interactions between the compound and the 
receptor remain unknown. 
1.4.2   Human histamine H3 receptor (H3)  
The H3 receptor inhibits histamine synthesis and release. It also negatively regulates 
the release of several other neurotransmitters, such as acetylcholine, dopamine and 
noradrenalin (Stark et al., 2001). The H3 receptor antagonists might offer a cure for 
memory disorders, narcolepsy, ADHD, arousal and cognition (Axe et al., 2006). The 
recently discovered receptor is located in the central and peripheral nervous systems. 
Its potential as a pharmaceutical drug target has invested H3 structural studies a high 
priority task. Structural information is also expected to improve the understanding of 
the specific ligand-binding behavior of other histamine receptors, such as H4, which 
has 81% identical residues around ligand binding positions. 
 
Because of the important role of H3 in drug development, functional research and 
computational work has been carried out since H3 was first cloned in 1999 
(Lovenberg et al., 1999). The outcomes provide some structural related information. 
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Atsuo and his co-workers have demonstrated that the carboxyl-terminus of H3 also 
plays a role in receptor inactivation, in particular the amino acid residue F8.50, which 
is involved in the transition of the receptor to its intermediate conformation, which is 
either ready to be activated, or inactivated (Kuramasu et al., 2011). F8.50 is believed 
to have interaction with the NPxxY motif to maintain the helix VIII at the right angle. 
The amphiphilic manner stimulates the RRTK polar residues in H3 to gather on one 
side, and the FFLL hydrophobic residues to move on the other side. The hydrophobic 
interface of helix VIII is responsible for the regulation of H3 activity, perphaps due to 
the stabilizing interaction between the interface and the plasma membrane. This 
region might be a potential target domain for H3 drug design. This information is 
useful for H3 construct design in structural studies.  
1.5   Macromolecular Crystallography 
Currently several techniques exist that provide spatial information on the atoms in 
macromolecules, like the membrane proteins studied in this thesis. After over 100 
years since its creation, X-ray crystallography is still considered the best experimental 
technique capable of revealing structural details at an atomic level. Perhaps the most 
important reason to try and determine the 3D structure of a macromolecule is the 
understanding of its biological function. Furthermore, detailed structural information, 
for example, the interactions between proteins or between proteins and other types of 
molecules, has accelerated the pace of drug discovery for specific targets.  
 
X-ray crystallography is a mature, but highly technical discipline. Membrane proteins 
introduce a further level of complication because, in general, they form less ordered 
crystals than soluble proteins. This feature is reflected in the acquisition of X-ray data 
of poorer quality and lower resolution, causing structure determination of membrane 
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proteins to be intrinsically more complicated than structure determination of soluble 
proteins. 
 
In this section the main aspects of X-ray diffraction from crystals of macromolecules 
will be outlined and the handling of the experimental data produced with this 
technique will be described through the use of some of the well-known computer 
programs used by the crystallographic community. The most important goal of crystal 
analysis is structure determination. What emerges from this analysis is a likely model 
of the macromolecule which can be validated both by the agreement with 
experimental data and with prior biological, chemical and stereo-chemical 
information.  
1.5.1   Why crystals? 
Ordinary light has a wavelength much larger than the typical size of the atoms 
forming a macromolecule. This is why proteins cannot be seen with conventional 
microscopes and, rather, need light of a much smaller wavelength. X-rays are best 
suited to provide atomic details for molecules and macromolecules. The scattering of 
X-rays by individual molecules yields weak intensities and, thus, cannot practically be 
used to produce detailed images. However, in recent years this is becoming more 
feasible thanks to the advent of powerful coherent X-ray sources like those produced 
by the X-ray Free Electron Lasers (XFELs). In order to bypass the limitation of the 
signal noise ration by a single molecule, orderly arrangement of several billion 
macromolecules in a single crystal can notably amplified the desired signal. In each 
crystal all the identical molecules are arranged in a three-dimensional array with a 
periodic order, called the lattice. The smallest repeating unit of this lattice is known as 
unit cell. There is no real physical lattice in a crystal, but this is a convenient 
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geometrical framework to simplify all theories and calculations connected with 
molecular analysis via X-rays. In fact, the way molecules pack together to form the 
final 3D crystal structure involves symmetrical arrangements of the same molecules 
via, for instance, rotations and roto-translations. Such symmetrical constructions are 
described mathematically with the so-called crystallographic space groups. These 
have been studied in detail and are listed in the International Tables of 
Crystallography. The importance of symmetry space groups in crystallography stems 
from the effect they have both on diffraction data and on macromolecular models. It is 
beyond the scope of this thesis to describe space groups in detail, but there are several 
books where the argument is treated in an approachable way for biologists. Here it is 
important to remember that the full content of a unit cell derives from symmetry 
operations performed on sub-units of the unit cell itself, called asymmetric units. It is 
also important to remember that length of the sides and angles of the unit cell are 
restrained by the specific space group. More specifically, space group symmetry 
determines the type of lattice and, thus, of unit cell compatible with that symmetry. 
There are in total 230 space groups which are comprised of a total of 14 lattices, 
known commonly as Bravais lattices, which could be grouped into 7 lattice system 
types (Table 1.3). 
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1.5.2   X-ray diffraction theory in a nutshell 
When monochromatic X-rays hit a crystal, they are scattered by the electrons of the 
atoms within the crystal lattice. Most of the scattered waves cancel each another by 
!! Lattice!systems!(7)! !Bravais!Lattices!!(14)!!
Triclinic!
!
Monoclinic!
!
Orthorhombic!
! ! !
Tetragonal!
! !
Orthorhombic!
!
Hexagonal!
!
Cubic!
! ! !!!!!!!!!!!!!!!!!!!!!!!!
Table	  1.3	  Seven	  lattice	  systems	  and	  14	  Bravais	  lattices	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destructive interference. However, some of them interfere constructively, giving rise 
to so-called diffracted intensities that can be captured and measured by appropriate 
detectors (Fig. 1.10). The spatial arrangement of the spots produced by the captured 
intensities can be used to determine the type of crystal lattice and the size of its unit 
cell. The relative strength of these spots (intensities) can be used to determine the 
arrangement of atoms in the asymmetric unit. 
 
The whole process can be conveniently described using the concept of the Fourier 
transform. The 3D arrangement in space of the intensities scattered by the crystal can 
be geometrically described by another lattice called the reciprocal lattice. In 
mathematical terms the Fourier transform of the crystal lattice is the reciprocal lattice. 
If the sides and angles of the reciprocal lattice (they could be called sides and angles 
of the reciprocal unit cell) are measured from the diffraction images, the sides and 
angles of the direct lattice can be calculated via the Fourier transform. In fact, once 
the spots relative intensities are also taken into account, an inverse Fourier transform 
Detector'
Crystal'
Diﬀracted'X1rays'
Incident'X1ray'beam'
Figure	  1.10	  A	  simplified	  schematic	  illustration	  of	  data	  collection.	  A	  monochromatic	  X-­‐‑ray	  beam	  is	  diffracted	  by	  a	  protein	  crystal,	  and	  the	  resultant	  diffractions	  are	  collected	  on	  a	  detector.	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can be used to determine the atomic structure forming the lattice. To be more specific, 
the scattered intensities (also known as reflections) represent only half of the 
information contained in the Fourier transform. The other half (phase information) is 
lost during the scattering process. Thus a starting model needs always to be “guessed” 
in order to make use of the inverse Fourier transform to determine a crystal structure. 
Such a “guess” can be determined by a detailed knowledge of the problem (as, for 
instance in this work, where an initial model for the protein was known and only the 
ligand molecule needed to be determined), or via probabilistic calculations whose 
details go beyond the scope of this thesis (for example direct methods, SAD phasing, 
molecular replacement, etc.). 
 
The reciprocal lattice points are uniquely described by a triplet of integers, known as 
Miller indices, usually designated as (h,k,l). The product of the X-ray diffraction of a 
crystal structure is a series of reflections (lattice points) given as Miller indices, with 
each reflection being associated to a diffracted intensity I. In a typical diffraction 
process by a macromolecule, several tens of thousands of intensities are measured 
during data collection, resulting in multiple measurements of the same reflection. It is 
this data redundancy that leads to improved accuracy in the measurement of I, which 
greatly facilitates structure determination, even when the phase information is lost 
during the diffraction process. 
1.5.3   The main steps in the structure determination process 
All efforts detailed in the present thesis to purify the proteins and obtain crystals that 
diffracted to a sufficient resolution, have been made in order to collect X-ray data, 
ultimately leading to structure determination. The full process of structure 
determination consists of tasks that can be different depending on the type of 
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macromolecular structure to be solved. In this section, the main steps followed to 
determine the structures of H1-cetirizine and H1-fenoxedine will be illustrated in 
details. As most of the tasks have been carried out using computer programs, these 
will be introduced in conjunction with the different structure determination steps.  
The whole structure determination work essentially consists of: 
1.   Data collection 
2.   Data processing 
3.   Data combination 
4.   Initial model determination 
5.   Model completion and model refinement 
1.5.3.1  Data collection 
When X-rays hit a macromolecular crystal, positively interfering scattered radiation in 
general occurs only along a small number of directions. Accordingly, only few 
diffraction spots are collected on the detector, when the crystal is kept still, with a 
fixed orientation. If the crystal rotates continuously around an axis, new scattering 
directions will occur at every new orientation of the crystal and many more reflections 
will be captured by the detector. To collect diffraction data from a crystal, it is 
necessary to mount the crystal in a stable frame and to rotate this frame when X-rays 
hit the crystal. The exact rotation range in this method of data collection (the rotation 
method) will depend on the crystal symmetry with higher symmetry space groups 
require smaller overall rotations to collect a complete data set. One important 
indicator of diffraction quality for macromolecular crystallographers is the distance 
from the center of each image and the position of the farthest away diffraction spots. 
The more distant spots provide higher resolution information. The crystals of H1-
cetirizine and H1-fenoxenadine described produced diffraction images with spots at a 
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maximum of 3 Å resolution. This is a reasonable resolution for crystals of membrane 
proteins and sufficient to build an atomic model. One of the most evident visual 
effects on diffraction images, as data collection proceeds on a single crystal, is the 
gradual disappearance of diffraction spots at high resolutions. This is due to the 
radiation damage caused by the energetic X-rays destroying chemical bonds in the 
crystal creating free radicals, that in turn destroying more chemical bonds. The overall 
effect, as the duration of exposure to X-rays increases, is the deterioration of the 
orderly lattice structure in the crystal and resultant loss of resolution. After a 
sufficiently long exposure time, eventually the disorder caused by radiation in the 
crystal lattice is so widespread that the crystal does not diffract any longer. The 
crystals of the membrane protein used in this study survived only briefly under the 
intense flux of the microfocused beam at the beamline I24 (Diamond Light Source). 
Thus, sufficient rotation sweeps to collect a complete data set only could be achieved 
from a relatively few crystals. Complete and statistically meaningful sets of 
diffraction intensities could be obtained with the combination of many incomplete 
(partial) sets of data, as explained below. 
1.5.3.2  Data processing 
The geometric spots of the 2D images produced during data collection must be turned 
into intensities associated with the 3D reciprocal lattice related to the crystal lattice. 
This task is carried out by the so-called integration programs, software specifically 
designed for integration of X-ray data. For the data collected in this thesis the 
integration program used has been XDS (Kabsch, 2010). XDS select a certain number 
of diffraction spots across all images and use their location in the 3D reciprocal space 
to determine cell parameters, lattice type and crystal orientation. Based on this the 
program predicts the position of all potential diffraction spots in the reciprocal space. 
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If the majority of the observed spots match such predictions, the program assumes 
that the specific choice for space group and cell parameters is correct and moves on to 
measure the intensity of each reflection. This involves, determining the spatial extent 
of each diffraction spot in order to add up the numerical strength of all pixels forming 
the specific spot, resulting in the integrated intensity. After all reflections have been 
integrated, the program outputs a file containing a list of integrated intensities with 
associated Miller indices and an estimate of the error in the intensity measurement. 
Such files are known as unmerged reflection files. The symmetry of the crystal lattice 
is transferred to a higher symmetry in the reciprocal lattice. For this reason, in 
general, all intensities are partitioned in groups of equivalent reflections. Due to the 
peculiar nature of the data collection experiment, intensities within each group are not 
exactly the same. Various and specific experimental issues cause the breaking of 
symmetry equivalence and, as a consequence, intensities of symmetry-related 
reflections, supposed to have exactly the same value, are different. For this reason it is 
necessary to correct numerically all groups of equivalent integrated intensities so that, 
after this operation, they are more similar with each other. This specific operation, in 
crystallography, is called scaling of data. The programs here used to carry out data 
scaling are AIMLESS included in the CCP4 suite (Collaborative Computational 
Project, 1994). All scaled intensities are written out to a new type of file as merged 
intensities (indicating the fact that they contain averaged values of each intensity).  
Structure factor amplitudes are extracted from scaled intensities and the merged 
reflections files are used for structure determination during phasing, model building 
and model refinement. 
 
To conclude this section, it is important to report the way in which data quality is 
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assessed in macromolecular crystallography. It is clear that if all symmetry-related 
intensities, after scaling, are very similar with each other, then their average, used as a 
representative scaled intensity and, thus, a representative structure factor for the 
specific reflection, can be determined with high precision. A measure of such 
precision is provided by three types of so-called R statistics, the Rmerge, Rmeas and Rpim 
(Evans, 2006). They are given by the following formulas: 
 
	  
 
Where the index l refers to all reflections with same Miller index h. Ih is the scaled 
observed intensity, <Ih> is the average of all scaled observed intensities with the 
miller index h, and nh is the number of symmetry-related reflections for miller index 
h. While Rmerge has been traditionally used by crystallographers for many years, in 
recent times it has been realized that this value does not take into account crystal 
symmetry. Rmeas obviates to this bias. The Rpim, like Rmeas, is not affected by 
symmetry, but, in addition, it takes into account how many symmetry-equivalent 
reflections, on average, were used for scaled intensities. Values of all the above 
statistics close to zero indicate data with a high level of precision. For soluble proteins 
it is likely to find values around 0.05, representing a 5% variation in measurements of 
the unmerged intensities, while for membrane proteins it is more likely to find values 
above 0.15-0.20. Data quality is also determined by the completeness in reciprocal 
space. This is essentially how many of the possible reflections in reciprocal space are 
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represented by the data set and is measured in percentage values. Data completeness 
is related to details and geometric distortions of the electron density. It is normally 
preferred to have datasets with completeness above 90%. To finish, data resolution is, 
quite obviously, important to convey a measure of data quality. Traditionally this was 
measured as signal-to-noise in resolution shells. This means that all data are 
partitioned in groups (shells) with similar geometric resolution and ratio of averages 
of intensities and their errors are calculated for each shell. Numerical values for this 
signal-to-noise indicator (termed Mn(I/sd(I))) start high and drop to small values as 
the geometric resolution increases. The resolution at which they reach the 1.5-2 limit, 
is considered the real resolution of the scaled data. For membrane proteins, and the 
H1 molecules investigated here are no exception, resolutions of potentially solvable 
structures are normally found between 3 and 4 angstroms. Recently another indicator 
of resolution the CC1/2 has been shown to be a useful. This is defined in the following 
way. Each group of symmetry-related reflections is randomly split in two halves and 
intensity averages are computed for each one of the two halves. The whole set of 
scaled data is, thus, split in two halves and correlations between the two halves, the 
CC1/2, can be computed for each resolution shell. If intensities reflecting the structure 
have been obtained from the scaling process, then both random halves will include 
such intensities and will display high correlation. When the noise starts to become 
comparable to the structural information (for instance, because it is measured at 
resolutions higher than the effective resolution of collected data), then the correlation 
will be low and CC1/2 will start to decrease. AIMLESS suggests data truncation when 
the CC1/2 falls below the 0.3 threshold. A more conservative choice prefers 0.5, rather 
than 0.3. 
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1.5.3.3  Data combination 
As previously mentioned most of the individual integrated datasets (i.e. data from a 
single rotation sweep) were not sufficient for structure determination. It has been 
possible to obtain complete datasets starting from the many incomplete ones, using 
one of the programs included in the CCP4 suite, called BLEND(Foadi et al., 2013). 
BLEND makes use of the cell 
parameters of each crystal to 
determines how much they differ 
from each other. The overall 
scenario of distances is 
summarized in a tree-like 
structure of similarities called 
dendrogram. (Fig. 1.11). The 
process through which a 
dendrogram is calculated is 
called cluster analysis and the 
various groups connected in a 
dendrogram are called clusters. 
BLEND produces scaled intensities for each cluster of the dendrogram. Each cluster 
is more complete than the component datasets and sufficient completeness is obtained 
for clusters in the upper part of the tree. The scaling of each cluster, in BLEND, is 
carried out using AIMLESS and POINTLESS. All statistics indicating data quality are 
reported for each cluster so that it is possible to judge and select the most convenient 
ones. Combinations of data different from the clusters are possible, as it will be 
explained in the description of data combination reported for the H1 structures in 
                Figure 1.11 A tree-like dendrogram. 
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Chapter 2. An important parameter used in BLEND is also an intuitive measure of 
clusters isomorphism. Clustering is achieved using the full set of unit cell parameters, 
but these do not provide an intuitive feeling for cells’ similarity, because they are 
more than just one number and because various linear transformations are applied to 
the original parameters before computing the dendrogram. To obviate this 
complication, an absolute Linear Cell Variation (aLCV) parameter has been added to 
the program to provide a linear absolute difference (in angstroms) between two or 
more unit cells. Consider two unit cells, A and B. Three diagonals, DaA, DbA and 
DcA are computed across the three faces of unit cell A. Similarly, three diagonals, 
DaB, DbB and DcC are computed across the three faces of unit cell B. The largest 
difference among DaA, DbA, DcA or among DaB, DbB, DcC is the aLCV. In a cluster 
with several unit cells, the highest aLCV computed across all couples in the cluster is 
the aLCV for the cluster. 
 
1.5.3.4  Intial data determination 
Molecular replacement was used to recover the information lost in the diffraction 
process: the phases of the structure factors. An initial model of the ligand free H-T4L 
structure and, accordingly, an initial set of phases, was already available (Shimamura 
et al., 2011). More specifically, both structures here solved are a combination of the 
H1-T4L complex with two different ligands. As these ligands form a very small 
fraction of the total structure, the solved model of H1-T4L will provide most of the 
information necessary to solve both H1-cetirizine and H1-fenoxenadine. What has 
been important for the structural work presented here is the alternation of model 
refinement and model completion carried out in several cycles and described in the 
following section. 
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An important assessment of the agreement between the initial model and data of is 
provided, once more, via R-statistics. This time the differences will be calculated 
between structure factor amplitudes from the model and structure factor amplitudes 
from the experimental data. Values, before refinement, of around 0.4 or less indicate 
some substantial agreement between the model and the structure, certainly a good 
starting point for structure refinement. But after completion, the modified (and 
completed) model is expected to reach an agreement with R around 0.2 or better. In 
recent years it has been found useful to adopt cross validation methods from statistics. 
Essentially, a number of reflections (around 10% of the total) are kept out of all 
crystallographic calculations (model completion and refinement), but they are then 
used to calculate the R statistics. Using the jargon developed by crystallographers, the 
R statistics calculated with most of the reflections is called Rwork while the one 
calculated using the unused reflections is called Rfree. What it is normally observed in 
a successful model completion / refinement process is both Rwork and Rfree decreasing 
towards low values. When the Rwork keeps decreasing, but the Rfree remains stable, this 
corresponds to an overfitting of the model parameters because the model is not 
entirely matching all the data and, rather, the structure is being biased towards the 
data used for refinement. In such instances it is better to reconsider modifying some 
parts of the model. 
1.5.3.5  Model completion and model refinement 
The initial model selected comes in the form of a so-called PDB file, an ASCII file 
including Cartesian coordinates of all atoms forming the structure and the 
corresponding isotropic vibrational motion around their centers, typically represented 
by positive quantities known as B factors or thermal factors. The higher the B factor, 
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the wider is the atom’s vibrational motion. When the atoms coordinates and B-factors 
are used in conjunction with the experimentally observed structure factor amplitudes 
(indicated as Fo), an inverse Fourier transform can calculate the electron density map 
(indicated as ρ) that represent a first approximation of the structure to be determined. 
In short, atomic coordinates and B factors can be used to calculate structure factors 
F=Fexp(iϕ), where F represents the structure factor amplitude and ϕ the structure 
factor phases. From the initial atomic model, via the direct Fourier transform, 
calculated structure factors Fc=Fcexp(iϕc) can be calculated. If an inverse Fourier 
transform is calculated with these quantities, the resulting electron density map 
exactly matches the initial model. As the purpose of the initial model is to 
approximate the structure to be determined, the initial electron density map needs to 
be somewhat different from the one reproducing the initial model. The phases ϕc 
always will have to be used to transfer structural information from the initial model, 
but the amplitudes Fc can be replaced. An option would be to use Fo, but it has been 
demonstrated that electron density maps calculated using 2Fo-Fc as structure factor 
amplitudes yields electron density maps least biased towards the initial model and 
reproducing the maximum possible amount of details of the structure to be 
determined. A useful, but different, electron density map is obtained using Fo-Fc as 
structure factor amplitudes. In this map the density corresponding to the initial model 
is essentially completely removed and the only density visible is the one 
corresponding to those atoms of the structure to be determined not contained in the 
initial model, and also tells if atoms are in the wrong place. 
 
The initial 2Fo-Fc map mostly has regions of electron density in which fits the atomic 
model. But there are also empty parts of density as well as parts of model not fitting 
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any density. This is what can be called an incomplete model, because it is mostly a 
complete representation of the final structure, but still needs some additional details. 
Such details must be provided manually by the macromolecular crystallographer, both 
trying to guess the best orientation to fit specific ligands and minor molecules, both 
using stereochemical expertise. The model building/model completion program used 
to carry out this task for the two H1 structures of this thesis is COOT (Emsley et al., 
2010). At each stage of partial addition to the initial model, all atomic coordinates and 
B factors have to be refined to achieve the best agreement with the experimental 
structure factor amplitudes and sensible existing stereochemical information. This 
task is performed by so-called refinement programs. The program used for the present 
work is the refine module in the PHENIX platform (Adams et al., 2010). 
1.5.4   Protein crystallization 
Obtaining well-ordered protein crystals is essential for protein structure determination 
through X-ray crystallography. In a protein crystal, millions of identical protein 
molecules are stacked up in a periotic lattice, this lattice acting as a three-dimensional 
diffraction grating when exposed to X-rays. Well-ordered crystals produce diffraction 
to higher resolution, allowing more detailed protein structures to be determined.  
 
In a crystallization experiment, the starting protein sample is in an aqueous 
environment, where proteins remain folded and functional. During the crystallization 
course, protein solubility is gradually changed in order to shift the system to a 
favorable state for crystallization. As shown in the protein solubility diagram (Fig. 
1.12), protein solution starts from an undersaturated state, which is transitioned into 
the supersaturation state, or more precisely, the nucleation zone, followed by crystal 
growth. 
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By increasing the protein or precipitant concentration, or both at the same time, the 
system shifts to the nucleation zone, where proteins form small microscopic clusters, 
referred to as nuclei. The nucleus could either lead to disordered structures, such as 
aggregates and precipitates, or to crystal growth. Crystal size will increase by 
consuming the free protein molecules in solution, until equilibrium is reached. 
 
Crystallization is a major barrier for crystallography, involving many challenges. 
Firstly, requiring a pure homogeneous protein sample: a rule of thumb being more 
than 97% purity. Furthermore, the whole process needs to happen under in an aqueous 
environment. Protein crystals are normally very fragile because of molecules are held 
by noncovalent bonds, such as hydrogen bonds, salt bridges, and hydrophobic 
interactions. This means that any movement of vibration might disturb the crystal 
growth. There are also many other factors that are known to affect crystal growth, 
including ionic strength, pH, temperature and the presence of additives. The chosen 
crystallization method and experimental setup could also have some influence. For 
membrane protein, the type of detergents is also an important consideration. 
 
In order to identify appropriate conditions for growing well-diffracting protein 
crystals for a given protein, all the factors mentioned above need to be tested and 
combined, which involves multiple steps of screening. 
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Figure 1.12 A simplified schematic representation of a protein crystallization diagram. The most 
commonly varied two parameters: protein and precipitant concentrations are used in the diagram. In order to 
reach crystal growth stage, the system starts from the undersaturated zone. Once reach the nucleation zone, then 
enters into the metastable zone followed by crystal growth. The route for vapor diffusion is marked by the green 
dash line. 	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1.5.4.1  Crystallization of integral membrane proteins (IMPs) 
Crystallization of integral membrane proteins (IMPs) is generally considered more 
challenging than for soluble proteins. Integral membrane proteins comprise 
amphipathic surfaces, being embedded in the membrane lipid bilayer in vivo. Once 
the proteins are extracted from the membrane during purification, detergents will 
wrap around their hydrophobic surfaces, which can, potentially, maintain them in a 
functional, folded conformation (Moller and le Maire, 1993).  As such, the actual 
molecules that are being crystallized are the protein-detergent complexes (PDCs). 
Selecting a detergent is therefore a critical step, which involves investigating two 
aspects of detergents, their effect on protein stability and on the formation of well-
diffracting crystals. Normally, long chain detergents form larger micelles, and in 
principle could stabilize IMPs better. However, they cover more of the protein 
surface, and decrease the area available to form protein-protein contacts, which 
normally leads to poor quality crystals. Using short chain detergents therefore seems 
an obvious solution. However, short chain detergents are less suitable for the 
solublization and stabilization of membrane proteins. Therefore, identifying a most 
suitable detergent involves a careful compromise of the two extremes. 
 
Apart from the various parameters discussed for soluble proteins and detergent 
selection, IMPs crystallization also involves some additional considerations, such as 
the use of additives (Smith et al., 1998) and antibody fragments (Ostermeier et al., 
1995). Fortunately, there are a large number of crystallization conditions that have 
been established from empirical screening rounds. Careful investigations on more 
parameters will give better success rate of obtaining the well-diffracting quality 
crystals. 
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1.5.4.1.1  Aqueous-based crystallization-Vapor Diffusion 
The various crystallization techniques, namely vapor diffusion, micro-dialysis and 
batch crystallization that are being employed on soluble proteins can also be applied 
to membrane proteins. Vapor diffusion is the most frequently used method, and the 
typical experimental setup involves either a hanging or sitting drop. In both 
experiments, a small volume of protein solution is mixed with a precipitant solution 
and left to equilibrate against a reservoir solution, containing similar buffers and 
precipitating agents (mainly salts and PEGs) to the precipitant solution. Due to the 
higher concentration of precipitants in the reservoir solution, water evaporates from 
the protein droplet, and the protein and precipitants concentrations increase, hopefully 
to a point within the nucleation zone that is required for producing crystals (Rhodes, 
1993). Crystals normally start to appear after a few days to weeks. The speed of 
crystallization mainly depends on the protein characteristics and the precipitants used. 
The method is normally carried out in several rounds with variations in precipitants, 
drop sizes and incubation temperature, etc., until the well-diffracting crystals are 
obtained. 
1.5.4.1.2  Lipid-based crystallization-Lipidic Cubic Phase (LCP) 
In the traditional aqueous-based membrane protein crystallization methods, the 
protein-detergent-complexes are exposed to the precipitant solution, posing a risk of 
denaturation and aggregation. These methods produce type II crystal packing, in 
which the crystal contacts are only between the hydrophilic surfaces of the molecules. 
With large areas of the protein surface covered by detergents, crystals have a high 
solvent content and consequently poor crystal packing (Ostermeier and Michel, 1997). 
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These problems could be overcome by lipid-based crystallization methods, including 
the bicelle (Faham and Bowie, 2002), vesicle (Takeda et al., 1998) and lipidic 
mesophase (cubic phase and sponge phase) (Landau and Rosenbusch, 1996) methods. 
Lipidic cubic phase (LCP), has been extremely successful for, but not limited to 
GPCRs (Landau and Rosenbusch, 1996). Crystallization of membrane proteins in 
lipidic cubic phase (LCP) is a method using LCP as a host medium, in which the 
protein-detergent-complex (PDC) is transferred into the lipid matrix, stabilizing the 
proteins and leading to type I crystal packing, in which the protein molecules make 
contacts through both hydrophobic and hydrophilic regions, resulting in a much better 
crystal packing (Landau and Rosenbusch, 1996). In the lipidic cubic phase method, 
lipids form a three-dimensional curved bilayer that is interpenetrated by water 
channels giving access to hydrophilic components as shown in Figure 1.13. As a 
result, this dynamic bicontinuous system can accommodate not only membrane 
Figure 1.13 Cartoon representation of the lipidic cubic phase and the crystallization process 
of membrane protein in the system.  
The protein molecules that reconstituted into the lipid bilayers in lipidic cubic phase are diffusing 
into the type1 crystal packing, which is in the lamellar phase. Lipid (tan), detergent (pink), protein 
(blue and green), cholesterol (purple), bilayer and aqueous channels (dark blue). The lipid bilayer is 
around 40 Å thick. (Figure was taken from Caffrey et al. 2009) 
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proteins in their native and active conformation, but also detergents, salts, additives, 
etc. The huge area of the interface between curved lipid bilayer and water channels is 
perfect for nucleation, followed by crystal growth through the lateral diffusion of 
protein molecules.	   
 
The most critical step of crystallization in LCP is the formation of this bicontinuous 
cubic phase, which is guided by the phase diagram. Monoolein has been the most 
successful lipid, its phase diagram (Fig.1.14) having been elucidated many times 
(Briggs and Caffrey, 1994, Qiu and Caffrey, 2000, Caffrey and Cherezov, 2009). 
 
A hypothesis for the mechanism was proposed by Caffrey: protein solution is mixed 
with lipid at an appropriate ratio under favored temperature (what is this), driving the 
system into a cubic phase (space group type Pn3m) (Fig. 1.14), which is in a viscous 
transparent form. During this process, the protein molecules are embedded into the 
lipid bilayer. Once the LCP bolus is overlaid by the precipitant solution (in excess 
volume), the components start to diffuse into the LCP matrix (molecular sponge) 
through the aqueous channels, triggering the phase transition towards the formation of 
the lamellar phase and crystal growth (Caffrey, 2003). 
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Figure 1.14 Moloolein/water phase diagram. Various phase states according to the water 
composition at a range of temperatures.	  20 °C is the most commonly used temperature, which is 
highlighted as a blue line. Lc, FI, HII, Lα, Ia3d and Pn3m represent lamellar crystal phase, fluid 
isotropic phase, inverted hexagonal phase, lamellar liquid crystal phase, cubic-Ia3d phase and 
cubic-Pn3m phase respectively. Blue and green colored areas represent water. Figure taken from 
(Caffrey and Cherezov, 2009) 
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2  Chapter Two 
Structural studies of the human 
Histamine receptor H1 in complex 
with second-generation 
antihistamines 
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2.1   Materials and Methods 
The protein expression, purification and crystallization steps were carried out closely 
following the published protocols (Shimamura et al., 2011), with modifications.	  
2.1.1   Expression 
2.1.1.1  Expression construct 
The construct used for the H1 study was engineered by (Shiroishi et al., 2011) based 
on the T4L method. It has been subcloned into a pPIC9K vector for the expression in 
Pichia pastoris and structural determination.  
 
In the H1 construct (Fig. 2.1), the N-terminus has been truncated from Met1 to Lys19 
as this region was suggested to be disordered by the secondary structure prediction 
servers, and including two N-linked glycosylation sites (Asn5 and Asn18), which are 
with the potential to affect the protein crystallization. The badly-structured third 
cytoplasmic loop (ICL3) has been replaced by the T4L mentioned above and the 
construct is followed by tobacco etch virus (TEV) protease cleavage site, green 
fluorescent protein (GFP) and octa-histidine (His8) tag. GFP tag is used to assist 
monitoring the target protein during the expression and purification steps, while the 
His8 tag is used for the immobilized metal ion affinity chromatography (IMAC) 
purification. The C-terminal region keeps the same length since it was supposed to be 
a short loop (Shimamura et al., 2011).  
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2.1.1.2  Generation and screening of expression colonies 
Pichia Pastoris SMD1163 strain was kindly given by Dr. Shweta Singh, MPC, 
Imperial College, London. Pichia Pastoris SMD1163 competent cells was made in-
house, with protocol by (Cregg et al., 1993). SMD1163 competent cells were mixed 
with PmeI linearized H1-T4L-GFP DNA and the plasmids transformed into 
SMD1163 Pichia Pastoris strain, using an Eppendorf electroporator (2000V). The 
cell suspension was plated on MD (Minimal Dextrose) agar plates (1.34% yeast 
nitrogen base w/o amino acids, 2% glucose, 0.00004% biotin and 1.5% agar) and 
incubated for 2-3 days at 30°C. 
 
The colonies that appeared on the MD-agar plates were harvested and serial dilutions 
were prepared. The equivalent of 105 cells/plate was spread on YPD (Yeast Extract 
Peptone Dextrose)-agar plate (1% yeast extract, 2% dextrose, 2% peptone, 2% agar) 
and supplemented with 0, 0.1 or 0.25 mg/ml geneticin (G418) to select those colonies 
containing the target gene. Incubation was carried out for 3-5 days at 30°C.  
 
Colonies that appeared on geneticin containing YPD-agar plate were brought to the 
small-scale expression trials. 
2.1.1.3  Small-scale expression test 
Single Pichia Pastoris colonies containing the H1 plasmid on YPD plates containing 
Figure 2.1. H1 construct. 
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0.1 mg/ml geneticin were picked. Each colony was inoculated with 5 ml of Buffered 
Glycerol Complex Media (BMGY) (100 mM potassium phosphate pH 6.0, 1.34% 
yeast nitrogen base w/o amino acids, 2% peptone, 0.00004% biotin, 1% yeast extract, 
1% glycerol). The culture was grown with a shaking speed of 250 r.p.m at 30 °C until 
an OD600 of 2-6 was reached. The cells were harvested by centrifugation at 3,000 g for 
10 min and the cell pellet was re-suspended in Buffered Methanol Complex Media 
(BMMY) (100 mM potassium phosphate pH 6.0, 1.3% yeast nitrogen base without 
amino acids, 2% peptone, 0.00004% biotin, 1% yeast extract, 0.5% methanol) 
containing 2.5% dimethyl sulfoxide to achieve a starting OD600 of 1 for all cultures. 
The culture was left to grow for 20 hours at 30 °C with a final OD600 of 13, and then 
the cells harvested by centrifugation at 5000 g for 5 mins.  
 
Cells were harvested by centrifugation at 3,000 g for 5 min after 20 hours and cell 
pellets re-suspended in 1xPBS buffer. GFP Relative Fluorescent Unit (RFU) of the 
cells were measured in an optical-bottom-black 96-well plate (Nunc, Rochester, NY) 
using a SpectraMax M2e (Molecular Devices). The machine settings were: emission 
512 nm, excitation wavelength 488 nm, bottom read, and the expression level was 
calculated as shown in box 1 (Newstead et al., 2007). The clone with the best 
expression level was picked and brought to large-scale expression. 
2.1.1.4  Large-scale expression of H1T-T4L 
The pre-culture was inoculated into BMGY in 2.5 Liters baffled flasks with 500 ml 
media in each flask. The culture was grown at 30°C and shaken at 250 rpm until an 
OD600 of 2-6 (log-phase growth, around 16-18 hours) was reached. The cells were 
harvested by centrifugation and the cell pellet was re-suspended in Buffered Methanol 
Complex Media (BMMY) with the addition of 2.5% (v/v) dimethyl sulfoxide 
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(DMSO) to achieve a starting OD600 of 1. After 22 hours, OD600 of the culture reached 
∼13. Cells were harvested by centrifugation, followed by flash freezing and stored at 
−80 °C. 
2.1.2   Purification of H1-T4L with antagonist 
2.1.2.1  Membrane preparation and membrane wash 
The yeast cell pellet was re-suspended in a breaking buffer containing 50mM HEPES 
pH7.5, 120mM NaCl, 5% (v/v) glycerol, 2mM EDTA and EDTA-free protease 
inhibitor cocktail tablets, by stirring at 4 °C until homogenized. Typically, 150 grams 
of cells were re-suspended in 360ml of ice-cold breaking buffer. The cells were 
broken using a cell disruptor (Constant System) by passing through the system four 
times at increasing pressures of 25, 30, 35 and 39Kpsi. Undisrupted cells and cell 
debris were separated and removed by centrifugation at 3,000 g for 20 minutes at 4°C, 
and then ultracentrifugation was used to collect yeast membranes at 100,000 g for 30 
minutes at 4°C. The membranes were then washed by the method of dounce 
homogenation, ultracentrifugation and re-suspension. Those steps were repeated 6 
times. The initial two washes was performed with buffer containing 10mM HEPES 
pH7.5, 5% (v/v) glycerol, 2mM EDTA and EDTA-free protease inhibitor cocktail 
tablets, and the following four washes were performed with the washing buffer 
Box 1: Numerical estimate of whole-cell overexpression level	  
  
Sample  RFU  /11,300RFU	  X    (0.03  mg  ml-­1)    =  GFP  Concentration	  	  
11,300   RFU:   Relative   Fluorescent   Unit   (RFU)   of   pure   yeast-­enhanced  
green  fluorescence  yEGFP  at  concentration  of  0.03  mg  ml-­1      
0.03  mg  ml-­1:  Concentration  of  pure  GFP  	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supplemented with 1M NaCl, 10 mM MgCl2, and 20mM KCl. The concentration of 
whole membrane proteins was estimated using the bicinchoninic acid method 
(Pierce). Washed membranes were flash frozen in liquid nitrogen and stored at 
−80 °C.  
2.1.2.2  Solubilization 
The membrane suspension was solubilized by incubation in the buffer containing 
20mM HEPES pH7.5, 500mM NaCl, 2% (v/v) glycerol, EDTA-free protease inhibitor 
cocktail tablets, 1% of n-dodecyl-β-d-maltopyranoside (DDM, Anatrace), 0.2% of 
cholesteryl hemisuccinate (CHS, Sigma), and the addition of 5 mM ligand and 
2mg/ml iodoacetamide, for 1-2 hours.  
2.1.2.3  First IMAC−Talon metal affinity Chromatography 
After the solubilization step, unsolubilized materials were removed using 
ultracentrifugation. The supernatant and pre-equilibrated TALON resin were mixed 
and stirred gently at 4 °C overnight. Talon resin was washed intensively in the wash 
buffer (20mM HEPES pH7.5, 500mM NaCl, 10% glycerol, 0.025% of n-dodecyl-β-d-
maltopyranoside, 0.05% of cholesteryl hemisuccinate) in the presence of 0.1 mM 
Ligand to get rid of the soluble protein, and the receptor was eluted using 200 mM 
imidazole in several fractions. All the fractions were checked by SDS–PAGE gel, and 
those H1-T4L-GFP containing fractions were pooled and concentrated to 2.5 ml. 
Then the PD-10 column was used to remove the imidazole. From this point forward, 
all steps have the presence of 0.1 mM ligand. 
2.1.2.4  Second IMAC−Ni-sephasrose affinity chromatography 
The protein was mixed to Ni-sepharose high performance resin and incubated for 1 
hour, then the flow through was collected, followed by 20 column volumes of wash 
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buffer (20mM HEPES pH7.5, 500mM NaCl, 10% glycerol, 0.025% of n-dodecyl-β-d-
maltopyranoside, 0.05% of cholesteryl hemisuccinate) with the presence of 0.5 mM 
Ligand (cetirizine and fexofenadine). Three column volumes of sample were eluted 
using 500 mM imidazole in different fractions. All fractions were assessed by SDS–
PAGE gel and the H1-T4L-GFP containing fractions were collected. 
2.1.2.5  Cleavage of GFP-His8 region and reverse IMAC 
The H1-T4L-GFP containing fractions from Ni-sepharose elution was mixed and 
incubated with His-tagged TEV protease for cleavage, and dialysed overnight in the 
dialysis buffer (20mM HEPES pH7.5, 500mM NaCl, 10% glycerol, 0.025% of n-
dodecyl-β-d-maltopyranoside, 0.05% of cholesteryl hemisuccinate and 1 mM Ligand) 
at 4 °C to get rid of Imidazole. The cleavage product was processed by reverse IMAC. 
In which the protein samples were applied onto the Ni-Sepharose high performance 
resin. The impurities that bound to the resins in the initial two IMAC steps will bind 
to the resin here again, while the H1-T4L, which has lost the GFP-His8 tag during 
cleavage, will be in the flow through, together with the first column volume washes 
were collected. The protein was concentrated to ∼40 mg/ml with a 100 KDa 
molecular weight cut-off Vivaspin concentrator and subjected to crystallization trials. 
2.1.3   Crystallization in Lipidic cubic phase (LCP) 
The Lipidic cubic phase mixture was prepared by mixing 40% (w/w) H1 solution, 
54% monoolein (MO) and 6% cholesterol. The crystallization trials were set up using 
the Mosquito-LCP robot (TTP Lab Tech, UK). The plates were set up using 50nl of 
protein-monolein dispensed on the glass sandwich plate with 800nl of precipitant 
solution dispensed on top of the lipidic cubic phase drop. All steps needed to be 
performed at 20-22°C, and the plates were incubated at 20°C. The precipitant 
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condition was: 24–33% PEG400, 10 mM MgCl2, 100 mM Na-citrate pH 4 - pH6.5, 
300 mM ammonium phosphate and 1 mM ligand (Sigma). 
2.1.4   Harvesting crystals from LCP 
MicroMounts loops (MiTeGen) were used to harvest LCP crystals from glass 
sandwich plates. The rigid design is helpful to harvest from the dense LCP material, 
and thinner design on loop area makes it easier to fish crystals grown on the bottom 
and helpful to lift the crystal from underneath. The whole design helps avoiding 
catching too much LCP material with the loops. 
2.1.5   Data collection and processing 
The crystals of H1 receptor in complexes were tested at the microfocus beamline I24 
at Diamond Light Source, using a beam size of 10 µm x 10 µm and a wavelength of 
0.96863 Å. The detector was a Pilatus 3 6M.  
 
Before data collection, the diffraction grid scan was applied in order to locate the 
crystal in the opaque LCP material on a MiTeGen loop and identify the best 
diffracting part on a tile-shaped crystal. For the grid scan, the crystal was exposed for 
0.01 second, with low transmission (5%) to minimize radiation damage. 
Two grid scans were carried out, 90° apart, in order to center the X-ray beam 
accurately on the best diffracting part of the crystal. 
 
Diffraction data for H1-cetirizne and H1-fexofenadine have been collected during 
several experiments. Crystals were always exposed for 0.2 second, with 50-70% 
transmission and an oscillation angular step of 0.2°. All data from the different 
crystals were integrated using the computer program XDS (Kabsch, 2010). Data that 
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could be successfully integrated were subsequently combined to form complete 
datasets, using BLEND (Foadi et al., 2013). 
2.1.6   Phenix-refinement 
The program Phenix (Adams et al., 2010) was used for phasing and refinement. The 
published structure of the H1-doxepin complex (PDB:3RZE) (Shimamura et al., 
2011), deprived of all ligands and non-protein atoms, was used as starting model. 
Rigid body refinement was followed by TLS (Translation-Libration-Screw rotation) 
refinement. For both strategies, two separate regions of the model were defined: T4L 
region as chain A (residue 28 to 485) and the rest as chain B (residue 1002 to 1161). 
Accordingly, both rigid body and TLS refinement were performed separately on the 
two regions. The refinement strategy was further modified on refinement targets and 
restraints. In particular, the reference model restraints and the secondary structure 
restraints were used because these useful for low-resolution data. The above 
refinement was monitored via R-value statistics (Rwork and Rfree), as these reflect the 
quality of the agreement between data and updated model. Different protocols of 
refinement were tried, in order to obtain the lowest possible R-factors with the 
minimal difference between Rwork and Rfree.  
2.1.7   Protein structure figure preparation 
Protein structure figures were generated with The PyMOL Molecular Graphics 
System (Version 1.7.4 Schrödinger, LLC.) and COOT (Emsley et al., 2010). 
2.1.8   Radioactive ligand binding assay (RLB) 
2.1.8.1  Site-directed mutagenesis and membrane production 
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The work for the site-directed mutagenesis and membrane production was carried out 
by Mr. James Birch from the Membrane Protein Laboratory of Imperial College at 
Diamond Light Source. Mutagenesis was performed using the QuikChange Lightning 
Multi Site-Directed Mutagenesis Kit (Agilent Technologies), following supplied 
instructions. The human H1 residues K179ECL2, K1915.39 and H4507.35 were mutated 
to Alanines, and five mutants were produced: K179A, K191A, H450A, 
K179A&K191A, K179A&K191A&H450A. In this chapter, the GPCR Ballesteros–
Weinstein numbering system (Ballesteros and Weinstein, 1995) are used for the key 
residues. Protein expression and membrane preparation were carried out following the 
published protocol (Shiroishi et al., 2012). The mutants were expressed in S. 
cerevisiae in small-scale, followed by membrane preparation. Final membranes were 
flash-frozen and stored at -80C° for radioactive ligand binding assays. 
2.1.8.2  Saturation radioligand binding assays 
Saturation radioligand binding assay is a technique to measure the specific binding of 
a radiolabeled ligand at various concentrations when the system reaches equilibrium. 
From it, ligand affinity and receptor density can be derived. The affinity of a ligand 
for a receptor is well described by the equilibrium dissociation constant, KD (nM). 
This constant describes the interaction strength between a ligand and its receptor. It is, 
in fact, the concentration of a ligand required to occupy 50% of the receptors. Bmax is 
the maximal number of receptor binding sites occupied by the ligand (pmol/mg) and it 
correlates to the amount of receptor present in the binding assay (Neubig et al., 2003).  
 
The saturation radioligand assays were carried out using the H1 ligand [3H]-
pyrilamine to determine the KD and Bmax of [3H]-pyrilamine of five different H1-T4L 
mutants plus the H1-T4L. In the binding reactions, yeast membranes bearing the H1 
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receptors containing 20 μg of protein were incubated with an increasing concentration 
of [3H]-pyrilamine (0.125, 0.25, 0.5, 1.25, 2.5, 5, 10, 20, 30, 40 nM) to define total 
binding. Non-specific binding for each concentration was determined under the 
identical conditions, in the presence of 40 nM unlabeled pyrilamine. Binding was 
performed in a buffer containing 20mM Hepes pH 7.5, 150mM NaCl of a final 
volume of 200 μl in a 96 well plate at 25°C for 2 hours to reach equilibrium. 
Following incubation, the free radioligands were separated from the bound 
radioligands by extracting the suspension onto Glass Fiber Filters (Packard, 
Groningen) under vacuum using a cell harvester (PerkinElmer). The filters were 
washed at least three times with Phosphate buffered saline (PBS) buffer (137mM 
NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM KH2PO4, pH 7.4) to remove remaining 
unbound radioactive ligands. They were then transferred into an oven incubated at 
40°C until they were completely dry. Dry filters were finally aligned to and mounted 
into the OmniFilter 96-well Microplate, 20 μl of MicroScintTM-O scintillation cocktail 
added to each well. The amount of bound tritium was counted using a Topcount 
Microplate scintillation counter (Packard/Perkin Elmer). All measurements were 
taken three times, simultaneously. The experiments were then repeated using a 
different buffer containing 20mM Na-phosphate pH5.8, 150mM NaCl to obtain the 
the KD and Bmax at a pH5.8. 
2.1.8.3  Data analysis: saturation binding assay 
What is measured from the scintillation counter is the amount of bound tritium for 
each total and non-specific binding reaction, expressed as counts per minute (CPM). 
From this the values of disintegration per minute (DPM) can be calculated using the 
equation: DPM=CPM/Counting Efficiency. The specific binding of radioligand in 
DPM was calculated using the equation: Specific bound=total bound-NSB. The free 
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(unbound) radioligand concentration for each reaction was calculated using the 
equation: Free=total added-total bound. DPM values were then converted to 
concentration units (i.e. pmol) by using the specific activity of radioligand [3H]-
pyrilamine (DPM/fmol). An Y vs X data table was created where the average specific 
bound radioligand concentration (pmol/mg) was plotted on the Y-axis against the free 
radioligand (nM) on the X-axis. Data were analysed using the Graphpad Prism 
version 5.00 for Mac OS X, GraphPad Software, San Diego California USA, 
www.graphpad.com. KD and Bmax were obtained by fitting the equation for the one-
site binding model using non-linear regression. 
2.1.8.4  Competition radioligand binding assays 
The competition binding assay is a method to measure the equilibrium binding of a 
fixed concentration radioligand in the presence of an unlabeled ligand (competitor) 
with various concentrations. The resultant data produce the value of IC50, which is 
used to calculate the equilibrium dissociation constant (Ki) of the competing ligand to 
the target receptor using knowledge of KD from the saturation binding assay. IC50 is 
the concentration of the competing ligand (unlabeled) required to displace 50% of the 
specific binding of the radioligand. It is essential to calculate the ligand affinity (Ki). 
Ki is the affinity, or equilibrium dissociation constant for the unlabeled ligand to the 
receptor that is calculated using the following Cheng-Prusoff equation (Cheng and 
Prusoff, 1973).  
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Where L is the concentration of radiolabelled ligand, and KD is the radioligand 
dissociation constant. The GraphPad software used for this analysis could produce the 
value of Ki using the above equation. 
 
The binding affinity (Ki) of H1 ligands cetirizine and fexofenadine to H1 mutants and 
H1-T4L were determined by competition radioligand binding assays against [3H]-
pyrilamine. In each reaction, yeast membranes bearing the H1 receptors containing 20 
µg of protein are incubated with an increasing concentration of unlabeled ligand 
cetirizine or fexofenaine (10-4, 10-4.5, 10-5, 10-5.5, 10-6, 10-6.5, 10-7, 10-8, 10-9, 10-10 M), 
and the radiolabeled ligand [3H]-pyrilamine with a fixed concentration of 30 nM. 
Total binding was measured in the absence of any competitor. Non-specific binding 
of the radiolabeled ligand was determined under identical conditions, in the presence 
of 40 nM unlabeled pyrilamine and absence of competing ligand. Binding was 
performed in the buffer containing 20mM Hepes pH7.5, 150mM NaCl of a final 
volume of 200 µl at 25°C for 2 hours to reach equilibrium. Following incubation, the 
free radioligands were separated from the bound radioligands by sucking the 
suspension onto Glass Fiber Filters (Packard, Groningen) under vacuum using a cell 
harvester (PerkinElmer). The filters were washed at least three times with Phosphate 
buffered saline (PBS) buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM 
KH2PO4, pH 7.4) to remove remaining unbound radioactive ligand. They were then 
transferred into an oven incubated at 40°C until they are complete dry. Dry filters 
were then aligned to and mounted into the OmniFilter 96-well Microplate and 20 µl of 
MicroScintTM-O cocktail were added to each well. The amount of bound tritium was 
counted using Topcount Microplate scintillation counter (Packard/Perkin Elmer). All 
measurements were taken three times, simultaneously. 
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2.1.8.5  Data analysis: competition radioligand binding assay 
Binding data were converted from counts per minute (CPM) to disintegration per 
minute (DPM) using the equation: DPM=CPM/Counting Efficiency. Specific binding 
(Bound-NSB) in the presence of competing ligand at different concentrations was 
converted to a percentage of the maximum specific binding using the equation: 
Specific bound (percentage)=(Bound-NSB)/(Total bound-NSB) x 100. The specific 
bond (%) was plotted on the Y-axis against the logarithm of the concentration (M) of 
the unlabeled ligand (X-axis). The data were analyzed by using the Graphpad Prism 
non-linear regression, choosing the one site-Fit Ki from the Competition binding 
equations panel. The software directly produces the value of Ki. 
 
Binding assay results, KD and Ki, are presented as pKD and pKi, which correspond to 
the negative logarithm of KD and Ki respectively (the logarithm is in base 10). 
 
Manual inspection, correction and rebuilding of the model, often in combination with 
cycles of refinement, was performed with the aid of the graphics program Coot 
(Emsley et al., 2010), using sigma-weighted |2Fo-Fc| and |Fo-Fc| maps. Mostly, the 
rebuilding focused on loops correction, addition of ligands and mutation of rotamers, 
all of this taking into account the fit with the electron density, the geometry and the 
ligand environment. 
2.2   Results  
2.2.1   H1-T4L clone selection and Large-scale expression 
Seven colonies containing the H1-T4L gene were obtained from the clone selection. 
The clones with a higher copy number of gene insertion were screened as mentioned 
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in method. They were brought to the small-scale expression trials and the best 
expression clone was selected based on GFP expression level. Large-scale expression 
was performed with the best H1-T4L expression clone. A total of 19 g wet cells per 1 
L culture were obtained. The GFP expression level was ∼0.1mg/ml, which is 
considered to be a sufficient yield for membrane proteins regarding to other published 
results (Newstead et al., 2007). The concentration of membrane proteins at this stage 
was estimated by the Bicinchoninic acid (BCA) assay (Pierce). From 12 L culture, 3 
mg of membrane proteins were obtained. 
2.2.2   Protein purification of H1-T4L with different antagonists 
Purification of H1-T4L with the presence of different antagonists was carried out by 
IMAC and reverse IMAC after cleavage of GFP- His8. Gel analysis (Fig. 2.2) shows 
that the protein has similar levels of purity as those in the published report by 
(Shimamura et al., 2011). Around 1 mg of pure protein was obtained, a sufficient 
amount for LCP crystallization trials. 
  
Figure 2.2. SDS–PAGE gel of H1-T4L from second metal affinity chromatography, 
TEV cleavage and reverse IMAC. (left) Visualized by Coomassie blue staining and 
(right) visualized by in-gel fluorescence.  	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2.2.3   Crystallization in Lipidic Cubic Phase 
Lipidic Cubic phase crystallization trials of H1-T4L with the ligands cetirizine and 
fexofenadine were set up with freshly prepared protein. Crystals appeared after 4-6 
weeks. Although these are crystals in complex with different ligands, they have very 
similar morphology. The largest obtained crystals are 50⋅50⋅10μm in size. 
2.2.4   Data collection and processing 
Crystals for both H1 complexes were grown from LCP. The common problem with 
the LCP crystals is that they cannot be visualized in the beamline visual setup. The 
grid scan function available at the Diamond 
Light Source (DLS) I24 beamline, has been 
extremely helpful to find H1 crystals in the 
completely opaque loop (Fig. 2.3). In 
addition, since different parts of the very 
thin tile-shaped H1 crystals diffract quite 
differently, the	  grid	  scan has been pivotal 
for maximizing the quality of the diffraction 
images obtained. 
 
It is very common to obtain fragile microcrystals from LCP trials. Useful X-ray data 
from H1 tiny crystals (50⋅50⋅10μm in size) were successfully obtained using the 
microfocus I24 beamline. Although other non-microfocus beamlines had also been 
tried initially, the diffraction images collected had a reduced signal-to-noise ratio 
compared to the microfocus beamline (data not included). I24 provided the small 
Figure	  2.3	  H1	  crystal	  and	  LCP	  
material	  in	  a	  cry-­‐‑loop.	  	  The	  red	  cross	  indicates	  the	  beam	  center,	  where	  the	  crystal	  is	  located,	  found	  by	  grid	  scan.	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focal and intense beam matching crystal size and making it possible to get the most 
out of the tiny H1 crystals. 	   
The fragile crystals deteriorated during the data collection due to the radiation 
damage, to such an extend that no complete data set could be obtained. Thus, even 
though large 90-degree rotation ranges were collected for each crystal, only the initial 
part of each collection contained useful data at the highest available resolution. In all 
subsequent images the resolution fell sharply as due to radiation damage. In the case 
of H1-cetirizine, for instance, only one dataset (number 11, as indicated later in the 
text) displayed a 98% completeness at a resolution of 3.3 Å, but the corresponding 
electron density map did not provide convincing details for the main ligand. For the 
analysis work carried out in this thesis, it has been essential to assemble partial 
datasets into complete ones, with the aim of producing maps with details of sufficient 
resolution. This task was carried out with the help of the recent BLEND software 
(Foadi et al., 2013) in the CCP4 suite of programs for crystallography (Collaborative 
Computational Project, 1994). With the aid of BLEND several complete datasets were 
obtained for both H1-cetirizine and H1-fexofenadine, including those eventually used 
to build interpretable models of the proteins and their ligands, as explained in the next 
two sections. 
2.2.4.1  Data processing for H1-cetirizine 
For the case of H1-cetirizine 35 continuous sweeps of data were collected from 19 
single crystals. As it turned out later, only 13 of these sweeps (from 7 single crystals) 
could be integrated with the XDS program. Only one of these datasets (serial number 
11) was complete and could be used for generating initial map and model, but the 
electron density around the ligand was of insufficient quality (Table 2.1).  
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Table 2.1 Parameters of thirteen datasets of H1-cetirizine  Serial	  Number	   Rmeas	   Rpim	   Completeness	  (%)	   Multiplicity	   Resolution	  (Å)	  CC1/2	  =	  0.3	  1	   0.305	   0.213	   16.8	   1.1	   3.2	  2	   0.693	   0.477	   17.2	   1.1	   3.8	  3	   0.170	   0.113	   37.7	   1.3	   3.1	  4	   0.180	   0.124	   25.8	   1.2	   3.2	  5	   0.468	   0.323	   23.7	   1.2	   3.8	  6	   0.387	   0.270	   24.3	   1.2	   3.8	  7	   0.293	   0.205	   16.2	   1.1	   3.5	  8	   0.269	   0.173	   60.0	   1.7	   3.0	  9	   0.274	   0.150	   65.1	   2.0	   3.0	  10	   0.350	   0.186	   67.3	   2.1	   3.5	  11	   0.379	   0.208	   98.1	   3.0	   3.3	  12	   0.296	   0.180	   59.0	   2.1	   3.3	  13	   0.338	   0.193	   65.7	   2.1	   3.3	  	  
The only other way to obtain complete datasets, as mentioned earlier, was to combine 
the 13 individual datasets into complete ones with higher redundancy. This could 
improve the accuracy of the scaled intensities, which, in turn, could improve map 
resolution around crucial zones of the protein and ligand. This is obviously strongly 
related to structure isomorphism. It is evident that data from two crystals of the same 
structure reproduce its finer details only if the structures various parts are oriented and 
translated in a highly correlated fashion in the two crystals. This is why the strategy of 
assembling complete datasets out of partial ones can be successful only if the 
composing crystals show a good amount of isomorphism. The analysis carried out for 
the two H1 structures has made use of the computer program BLEND for multiple 
crystals data management, precisely with the purpose of assessing crystals 
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isomorphism. The very first assessment is done using cell parameters as similarity 
descriptors. In very simple terms, two crystals, or different parts of the same crystal, 
are similar if their cell parameters are close to each other. Isomorphism for the 13 
datasets under analysis is depicted by the dendrogram (Fig. 2.4), and it is the result of 
a cluster analysis process carried out using cell parameters as statistical descriptors.  	  	  
 
Figure 2.4 Dendrogram of cluster analysis on cell parameters of H1-cetirizine. 
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Twelve clusters were formed out of 13 datasets. The numbers in red are the individual 
datasets, while the white numbers in the grey boxes correspond to specific clusters. 
Numbers in blue are the absolute Linear Cell Variation (aLCV) and are measured in 
angstroms. They provide a measure of datasets similarity; the smaller the aLCV value, 
the closer the datasets. BLEND generates scaled data for every cluster displayed in 
the dendrogram. The working resolution for all scaling jobs was fixed at 3 Å in order 
to make comparisons simpler and to enable details at higher resolution to be visible as 
much as possible. The result is displayed in Figure 2.5. 
 
Figure 2.5 Merging statistics for clusters formed with H1-cetirizine datasets 
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 The dendrogram in Figure 2.5 has the same structure of the dendrogram in Figure 
2.4. Here, clusters are indicated by grey circles, rather than boxes, and three numbers 
are displayed with different colours around each circle. The number in green indicates 
completeness, the number in red indicates resolution as estimated by the CC1/2 
parameter, and the number in blue is the Rmeas statistics, indicating how well 
intensities merge together.  It is quite clear from the dendrogram that the resolution is 
extended by the inclusion of datasets. This is why top clusters 11 and 12 have a 
resolution of 3A based on CC1/2 being greater than 0.3. Rmeas values, though, are not 
great. This should be correlated with an increasing non-isomorphism following data 
accumulation, as quantified in the dendrogram at Figure 2.4. These numbers can be 
improved by filtering out specific datasets in the BLEND process known as 
combination, where groups of datasets different from the clusters are tried to see if 
certain statistics improve. A close inspection of Figure 2.5 will convince the reader 
that all combinations should start by including the branch on the right, because 
branches on the left of the dendrogram are not complete and have lower isomorphism 
(higher values of the absolute Linear Cell Variation). Thus, starting from cluster 5, 
one or two individual datasets are removed in an attempt at improving resolution from 
3.2 Å and/or improving the Rpim, because the last statistics takes into account both 
merging quality and data multiplicity. It turns out that removing datasets 1 and 10 
from cluster 5 improves the Rpim, which goes from 0.206 to 0.181 (Table 2.1). Next, 
dataset 4 is added to the filtered cluster 5, so to produce a filtered cluster 6. The 
resolution is unchanged, while the Rpim improves, going from 0.181 to 0.171. Then 
dataset 7 is included in the filtered cluster 6, so to produce a filtered cluster 8. This 
time both resolution and Rpim essentially remain unchanged. We know that the 
inclusion of the remaining datasets to form clusters 9, 11 and 12 is beneficial to 
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resolution. Thus more datasets can be added to the filtered cluster 8, in an attempt at 
improving numbers. Eventually the best result comes from the filtered cluster 11, 
while the filtered cluster 12 provides slightly worst statistics.  
 
The filtered cluster 11 was finally selected for the subsequent steps in crystallographic 
structure analysis. As the highest resolution suggested by the scaling programs 
AIMLESS, in terms of signal-to-noise being greater than 1.5, was 3.22 Å, it was 
decided to adopt a conservative approach to model building and refinement and 
provide input data at 3.2 Å resolution. Merging statistics for the final dataset are 
displayed in the first part of Table 2.2. 
Tabel 2.2 Merging statistics for the final dataset Starting	  Cluster	   Datasets	  Filtered	  out	   Rmeas	   Rpim	   Completeness	  (%)	   Multiplicity	   Resolution	  (Å)	  (CC1/2	  =	  0.3)	  5	   1,	  10	   0.387	   0.181	   99.6	   4.2	   3.2	  6	   1,	  10	   0.379	   0.171	   99.5	   4.5	   3.2	  8	   1,	  10	   0.391	   0.173	   99.5	   4.7	   3.2	  9	   1,	  10	   0.409	   0.148	   99.8	   7.1	   3.1	  11	   1,	  2,	  10	   0.400	   0.129	   100	   8.8	   3.0	  12	   1,	  2,	  5,	  10	   0.417	   0.132	   99.9	   9.1	   3.0	  	  
To conclude this section it is interesting and, in fact, illuminating to show the 
dramatic improvement in terms of resolution and map quality obtained with the 
inclusion of multiple datasets. In Figure 2.6 correlation plots of the type CC1/2 versus 
resolution are displayed for three different datasets. The black curve describes the 
behavior of the only complete single dataset 11; the red curve comes from cluster 11 
and the green curve from the same cluster, filtered of some individual datasets. While, 
resolution wise, filtering does very little to improve matters, it is quite evident, and 
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indeed striking, the improvement when enriching dataset 11 with other isomorphous 
data. As mentioned earlier, this is ultimately caused by an increased multiplicity and 
by the elimination of bias brought in by the use of independent crystals. 
	  
Figure 2.6 correlation plots of the type CC1/2 versus resolution are displayed for three different 
datasets. 
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Figure 2.7 X-ray diffraction of H1-cetirizine complex (left). Crystal of H1 receptor in the 
complex with cetirizine grown in LCP (up right). Weak diffraction spots are visible at 2.7 Å 
(bottom right).  	  
100μm 	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Table 2.3: Data collection, processing and refinement statistics for H1-cetirizine 
Data collection and processing  
Beamline  DLS-I24 
Space group I422 
Unit cell parameters 
a, b, c (Å), α, β, γ (°) 
a=87.73, b=87.73, c=331.32 
α,β,γ=90 
Wavelength (Å) 0.96863 
Resolution range (Å) 49.68-3.2 (3.42-3.2) 
Number of reflections  105443 (18344) 
Number of unique reflections 11226 (1975) 
Rmerge (%)  31 (128) 
Rmeas (%) 32.8 (135) 
Rpim (%) 10.6 (42) 
Completeness (%) 100 (100) 
Mean I/σ (I)  6.5 (1.8) 
Multiplicity  9.4 (9.3) 
Mn(I) half-set correlation CC(1/2) 0.99 (0.57) 
 
Model Refinement  
Resolution (Å)          3.2  
Rwork (%)  24.4 
Rfree (%) 28.6 
Average B factor after TLS refinement 
(Å2) 
91.3 
  
r.m.s.d. from ideal values  
r.m.s.d. bond length (Å)                                 0.011  
r.m.s.d. bond angles (°) 1.8 
  
 
Values in parentheses refer to the highest resolution shells. 	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2.2.4.2  Data processing for the datasets of H1-fexofenadine 
For the case of H1-fexofenadine, 28 datasets were collected from 5 crystals. 
Completeness and other statistics are described in Table 2.4.  
Table 2.4 Parameters of 28 datasets of H1-fexofenadine 
Serial 
Number 
Rmeas Rpim Completeness (%) Multiplicity Resolution (Å) 
(CC1/2 = 0.3) 
1 0.364 0.243 83.9 1.7 3.5 
2 0.808 0.494 68.7 1.8 3.7 
3 0.600 0.384 74.1 1.9 4.0 
4 >1 > 1 79.6 1.7 6.2 
5 0.622 0.341 50.5 2.6 3.9 
6 > 1 > 1 63.2 2.1 4.4 
7 > 1 > 1 60.2 2.1 5.5 
8 0.332 0.228 32.9 1.5 4.1 
9 0.255 0.164 42.7 1.9 3.3 
10 > 1 > 1 51.0 2.2 5.0 
11 > 1 > 1 31.2 3.3 6.0 
12 0.428 0.246 49.9 2.7 4.0 
13 0.226 0.150 42.0 1.4 3.2 
14 0.372 0.252 36.0 1.4 3.7 
15 0.637 0.353 54.7 2.2 3.8 
16 0.903 0.545 56.5 2,2 4.5 
17 0.607 0.363 63.0 2.0 3.8 
18 > 1 > 1 67.6 2.0 4.2 
19 0.513 0.275 39.8 3.0 3.7 
20 0.328 0.192 54.4 2.3 3.4 
21 0.572 0.295 89.8 3.1 3.5 
22 0.595 0.404 84.8 1.6 3.8 
23 0.236 0.142 53.2 1.9 3.1 
24 0.447 0.294 78.9 1.7 4.0 
25 0.772 0.427 72.6 2.7 4.2 
26 > 1 > 1 83.9 1.6 5.0 
27 0.222 0.134 75.1 2.2 3.2 
28 > 1 > 1 72.1 2.2 4.2 	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As it was the case for H1-cetirizine, also in this case no single dataset has been 
deemed sufficiently good to calculate interpretable electron density maps. Therefore 
BLEND was used also in this case to try and improve both merging statistics and 
resolution. Cluster analysis performed on all 28 datasets resulted in the dendrogram 
shown at Figure 2.8. 
	  
Figure 2.8 Dendrogram of cluster analysis on cell parameters of H1-fexofenadine 
  
All 28 datasets, in general, manifest substantial non-isomorphism. In fact, the absolute 
Linear Cell Variation for all datasets amounts to 22.98 Å. Of the two branches 
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splitting from the top cluster the one on the right has lower aLCV and, therefore, is 
the one best placed to provide a complete set with good-quality data. To cut a long 
story short, after having assessed merging statistics for all clusters under cluster 26, 
and after having filtered out bad quality data, a final complete dataset was obtained as 
union of the individual datasets 2, 8, 9, 13, 22, 23 and 27. From Figure 2.8 it is 
immediate to notice that these numbers belong all to cluster 23. It has been in fact 
possible to obtain a clear electron density map for cluster 21 as well, but in this case 
the density for fexofenadine was less defined. Final statistics for the chosen complete 
dataset are displayed at Table 2.5. 	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Figure 2.9 X-ray diffraction of H1-fexofenadine complex (left). Crystal of H1 receptor in the 
complex with fexofenadine grown in LCP (up right). Weak diffraction spots are visible at 3 Å 
(bottom right).  	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Table 2.5: Dataset collection, processing and refinement statistics for H1-
fexofenadine 
Data collection and processing  
Beamline  DLS-I24 
Space group I422 
Unit cell parameters 
a, b, c (Å), α, β, γ (°) 
a=87.4, b=87.4, c=331.22 
α,β,γ=90 
Wavelength (Å) 0.96859 
Resolution range (Å) 43.7-3.4 (3.67-3.4) 
Number of reflections  32503 (4943) 
Number of unique reflections 8477 (1460) 
Rmerge (%)  15.7 (52.6) 
Completeness (%) 91.3 (78.6) 
Mean I/σ (I)  6.9 (2.5) 
Multiplicity  3.8 (3.4) 
Mn(I) half-set correlation CC(1/2) 0.992 (0.564) 
  
Model Refinement  
Resolution (Å) 3.2 
Rwork (%) 22.7 
Rfree (%) 28.6 
Average B factor after TLS refinement (Å2) 100.81 
  
r.m.s.d. from ideal values  
r.m.s.d. bond length (Å) 0.012 
r.m.s.d. bond angles (°) 1.7 
  
 
Values in parentheses refer to the highest resolution shells. 
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2.2.5   Data quality 
The structures of H1 in complexes with cetirizine and fexofenadine were both solved 
by molecular replacement using the structure of H1-doxepin complex as a model. The 
final resolutions of the complex structures are 3.2 Å and 3.4 Å respectively. The R-
values from refinement are Rwork=24.4%, Rfree=28.6% for H1-cetirizine and 
Rwork=22.7%, Rfree=28.6% for H1-fexofenadine. They both have reasonable 
geometries. In the Ramachandran plot, the model of H1-cetirizine is with 95% in the 
preferred regions and 1.18% of outliers, while the model of H1-cetirizine is with 95% 
in the preferred regions and 1.89% of outliers. 
 
The overall protein structure and electron density quality are quite consistent among 
H1-cetirizine, H1-fexofenadine and the published H1-doxepin (Shimamura et al., 
2011) complexes. The quality of the electron density maps of H1-cetirizine and H1-
fexofenadine are illustrated in Figure 2.10. 
 
Figure 2.10 Partial electron density maps for H1-cetirizine complex (left) and H1-
fexofenadine (right). |2Fo-Fc| map contoured at 1σ. 	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Electron densities of most residues in the regions involved in the inter-helical contacts 
and ligand-binding site are well defined. The weaker densities were observed for 
residues on the flexible loop regions, as well as helix I and helix VIII, which are both 
not in tight contact with transmembrane core. These features of electron density 
quality are commonly observed for this range of resolutions in family A GPCRs 
(Rasmussen et al., 2007, Kruse et al., 2012, Granier et al., 2012). 
For both H1-cetirizine and H1-fexofenadine complexes, most of the electron densities 
allowed the modeling of protein residues, apart from a section of extracellular loop 2 
(residues F168-V174), which is not included since the electron density for it is not 
contiguous. This missing loop section also occurred in the H1-doxepin structure, 
which was solved at 3.1 Å (Shimamura et al., 2011). The omit maps for cetirizine and 
fexofenadine (Fig. 2.11) have allowed the initial fitting of the ligands into the right 
binding site.  
 
Figure 2.11 |Fo-Fc| omit maps for cetirizine (left) and fexofenadine (right). |Fo-Fc| omit maps 
are contoured at 3 σ, and shown as green mesh, cetirizine and fexofenadine are shown as purple 
sticks. 
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2.2.6   Crystal structures of H1 in complexes with cetirizine and 
fexofenadine 
2.2.6.1  Subregions of H1 ligand binding site 
The crystal structure of H1 in complexes with cetirizine and fexofenadine share the 
backbone structure with H1 in complex with doxepin. The main focus of the 
structures is on the ligand binding site. The binding pocket in H1 is a relatively deep 
cavity with the entrance on the extracellular side. There are some special features of 
the binding pocket, which are used to divide the pocket into three subregions: the 
lipophilic subsite, the D1073.32 ionic interaction region, and the anion binding site as 
shown in Figure 2.12. The region at the binding pocket bottom is highly hydrophobic, 
which comprises of a cluster of aromatic residues. This highly conserved region is 
lipophilic	  subsite	  	  D1073.32	  ionic	  interaction	  region	  	  hydrophilic	  binding	  domain	  
Figure	   2.12	   Subregions	   of	   H1	   binding	   pocket.	   The	   three	   subregions	   of	   H1	   binding	  pocket	  are	   illustrated	   in	  the	  H1-­‐‑cetirizine	  structure.	  Lipophilic	  subsite,	  D1073.32	  binding	  region,	   and	   hydrophilic	   binding	   domain	   are	   shown	   in	   blue,	   yellow	   and	   ruby	   shade	  respectively.	   H1	   receptor	   is	   shown	   as	   cartoon	   representation,	   cetirizine	   is	   shown	   as	  orange	  sticks.	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called the “lipophilic subsite”. The “anion binding site” around the entrance region is 
with a great degree of variations across aminergic GPCRs. The acidic	  residue 
D1073.32, which is highly conserved for aminergic GPCRs is the most important 
residue, always forms a salt bridge with the amine moiety of agonists, antagonists and 
the receptor’s natural ligands (Moguilevsky et al., 1998; Nonaka et al., 1998; Ohta et 
al., 1994). 	  
The electron densities of the “lipophilic subsite” and the “D1073.32 ionic interaction 
region” for both complexes are quite well resolved (Fig. 2.13, Fig. 2.14), hence the 
residue side-chains of these two regions were modeled confidently.  
However, the side-chains of the residues at the “anion binding site” on the 
Figure 2.13 Electron density of the “lipophilic subsite” for H1-cetirizine complex (left) and 
H1-fexofenadine (right). |2Fo-Fc| map contoured at 1σ. 	  
Cetirizine	   Fexofenadine	  
Figure 2.14 Electron density of the “D1073.32 ionic interaction region” for H1-cetirizine 
complex (left) and H1-fexofenadine (right). |2Fo-Fc| map contoured at 1σ. 	  
D1073.32 	   D1073.32 	  
Cetirizine	   Fexofenadine	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extracellular side have weak 
electron density for both 
complexes. Especially the long 
lysines, K179 on extracellar 
loop 2 and K191 on helix V, 
the density of the side-chains 
are totally missing (Fig.2.15). 
The “anion binding site” in 
crystal structure was first 
describe with the H1-doxepin 
structure, where it is 
coordinating with a phosphate 
ion.	   An inspection on the 
electron density map of the 
published H1-doxepin complex 
(Fig. 2.15 bottom) revealed that 
the lysines in this structure do 
not have any electron density 
either, although the binding site 
including residue K179, K191 
and H450 was reported in the 
literature (Shimamura et al., 
2011). In the structures reported in this thesis, the two lysines were left as they are 
after refinement.	  	   	  
Ce#rizine(
K179ECL2(
K1915.39(
H4507.35(
Fexofenadine(
K179ECL2(
K1915.39(
H4507.35(
PO43>(
K179ECL2(
K1915.39(
H4507.35(
Figure 2.15 Electron density of “anion binding site” for 
H1-cetirizine complex (top), H1-fexofenadine (middle) 
and H1-doxepin (bottom). |2Fo-Fc| map contoured at 1σ. 	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2.2.6.2  Interactions between cetirizine and H1 receptor 
The second-generation antihistamine cetirizine contains a modified diphenylmethyl 
moiety, with a chloride attached to one of its benzene rings. The diphenyl ring system 
adopts a butterfly-shaped conformation in the crystal structure, having the benzene 
rings mimicking two spreading wings as shown in Figure 2.16. Cetirizine is a racemic 
mixture of R-cetirizine and S-cetirizine. However, the difference between the two 
configurations in the crystal structure is too small, beyond the obtained x-ray data. In 
theory, it would be impossible to decide which configuration to put in.  An 
isomorphous difference map calculated from H1-cetirizine and H1-doxepin data 
revealed the positive electron density corresponding to the position of the chlorine, as 
indicated in Figure 2.17, hence the cholorbenzene ring was placed in this density, 
indicating only S-cetirizine has been observed in the crystal structure. 
The chlorobenzene ring points almost perpendicularly down to the intracellular 
membrane plane, while the benzene ring projects towards helix V (Fig.2.16).  
Figure 2.16 Cetirizine in H1-cetirizine 
complex. Cetirizine is shown as orange 
sticks. Ribbon representation of H1 
receptor structure, cartoon representation 
of helix V as an object of reference to 
the position of cetirizine.  	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As shown in Figure 2.18, the diphenylmethyl moiety in cetirizine is responsible for 
the extensive hydrophobic interactions with the receptor. The benzene ring is in van 
der Waals contact with residues including Y108, W158, A195, Y431, F432 and F435 
on helix III, V and	  VI. While the chlorobenzene ring only is within van der Waals 
contact distance of F432 and W428. The edge-to-face π-stacking interaction with 
F435 made the major difference on the protein, which will be described in the 
following section.  
A piperazine moiety is directly attached to the diphenylmethyl group, via one of its 
nitrogens. The piperazine moiety anchors to the protein by forming a salt bridge with 
the most conserved residue D1073.32. This important residue is the binding site for H1 
natural agonist histamine. As showen in figure 2.18, it is obvious that the 2.5Å 
distance between D1073.32 and the nitrogen b (marked with blue circle in Figure 2.19) 
is much shorter than with nitrogen a (marked with blue circle in Figure 2.19), and 
forms a strong salt bridge. The two amine groups of the piperazine moiety have  
Levocetirizine	   (R-­‐‑cetirizine) 
S-­‐‑cetirizine 
Figure 2.17 Isomorphous difference map. Calculated from H1-cetirizine data and H1-doxepin 
data. The electron density at the position of the chlorine is in blue circle. |Fo-Fo| map contoured at 
3 σ. 
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different protonated states under various pH environments. The distribution of their 
protonation microspecies at different pHs were predicted using the protonation bundle 
of software ChemAxon (http://www.chemaxon.com) (Fig. 2.10). At pH 7.5, the 
microspecies distribution of cetirizine is 50% of 4, 15%	  of 5 and 35% of 1 
Figure 2.18 Cetirizine binding pocket. a. Direct view on polar contacts with the receptor; b. 
direct view on the “lipophilic subsite”.	  Cetirizine is shown as orange sticks, H1 receptor is shown 
as cartoon presentation, residue side chains are shown as yellow sticks, polar contacts are shown 
as red dash lines. 
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microspecies; while at pH 5.8, the distribution is 75% of 4, 24% of 5 and 1% of 1 
microspecies.  
The protein was produced at pH 7.5, however the crystals were obtained at pH4.5-5.5. 
The exact pH along the binding pocket of the receptor is not known. It is assumed to 
be similar to the extracellular environment but it will more likely to be a gradient 
between the extracellular and intracellular pH.	   
The proportion of protonated amine group b (Fig. 2.19) is larger at acidic pH, where 
reaches the highest of 75% at pH5.8, and the overall proportion of protonated amine 
groups in cetirizine is larger at acidic pH, and at pH5.8 reaches a peak. This could 
lead to the conclusion that the ligand binds to the protein tighter at acidic pH, and 
results in more stable conformation, hence explains why crystals were grown at acidic 
pH. Or what was captured in the crystal structure was the conformation of only 
nitrogen b is protonated, and the salt bridge only forms between Asp1073.32 and 
nitrogen b. 
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The carboxyl group is connected to the piperazine moiety through a flexible ethoxy 
chain. This carboxyl group is protonated at all pHs within the experiment. It 
potentially could form salt bridges with K191. A potential hydrogen bond could be 
formed between Y431 and ligand carboxylate group. 
The diphenyl ring system of cetirizine sits quite firmly in the “lipophilic subsite” of 
the binding pocket, and the piperazine moiety is anchored tightly by the D1073.32, 
while on the other side of the ligand, the carboxyl group is sticking out towards the 
extracellular side, interacting with the flexible extracellular domain. 
Figure 2.19 pKa based microspecies distribution (%) of cetirizine. The microspecies 1, 4 and 5 
are present in the pH5.5 to pH 7.5. 	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2.2.6.2.1  Comparison of cetirizine and doxepin in the binding pocket 
of H1 receptor 
Overall, cetirizine sits in a similar position to doxepin. Superimposition of the two 
ligands in H1-cetirizine and H1-doxepin complexes shows the ligands are almost 
overlapped at the benzene ring region and the amine moiety. Although doxepin is 
much shorter than cetirizine, an anion-binding site was identified in the H1-doxepin 
structure, and a phosphate ion was modeled into it. The carboxyl group on cetirizine is 
at the same binding site as phosphate in H1-doxepin structure (Fig.2.20).	   
Figure 2.20 Superimposition of doxepin, phosphate ion and cetirizine. Cetirizine is 
shown as orange sticks, doxepin is shown as green sticks, phosphate ion is shown as golden 
sticks. Cartoon representation of H1 receptor structure. The residues form salt bridges with 
the ligands are shown as lines in the matching color with the ligands. 	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Doxepin is interacting with the receptor only in the “lipophilic subsite” and the highly 
conserved residue D1073.32. Cetirizine has a more extended structure. Its carboxyl 
group on the other end of the ligand is sticking out to the extracellular domain, 
interacting with the “anion binding site”. It binds similarly as the phosphate ion 
identified at the same position in the H1-doxepin structure (Fig. 2.20).  
Although doxepin binds very tightly with the receptor, the residues involved in 
binding are quite conserved in other GPCRs. Cetirizine, on the other hand, forms salt 
bridges with the receptor on the “hydrophilic binding domain”, which is specific to 
the H1 receptor, hence ensured the specificity of this second-generation antihistamine.  
In the structure of H1-doxepin, the ligand is too short to interpret the extracellular 
region of the binding pocket, but the “anion-binding site” is proposed by Iwata and 
his colleagues (Shimamura et al., 2011) to be responsible for the specific binding of 
non-classical antihistamines. Here, this assumption has been first time proved by a 
crystal structure. The “anion-binding site”, which in this these called “the hydrophilic 
binding domain”, indeed is interacting with the carboxyl group of cetirizine through 
H1 specific residues.  
2.2.6.2.2  Position of residue F4356.55 
The H1 receptor in H1-doxepin complex shares the same scaffold as in H1-doxepin 
complex, including the conserved GPCR microdomains, such as CWxP, D(E)RY, 
NPxxY motifs and disulphide bonds. 
 
Although the backbones of the receptor in both complexes can be almost entirely 
overlaid, some differences on the residue side chains have also been observed. The 
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most obvious difference between the two structures is the position of residue F4356.55. 
Compared with H1-doxepin complex, the F4356.55 side chain in H1-cetirizine complex 
moved away from the transmembrane core, with helix VI as a rotational axis. There is 
a 3Å distance between the benzene ring centers in the two complexes. The benzene 
plane of F4356.55 was also adjusted to a best angle to be perpendicular to the benzene 
ring on cetirizine. Their positions are defined very well on the electron density maps 
as shown in Figure 2.21. 
 
By taking a closer observation on this residue and its near vicinity in both complexes, 
a conclusion was made that the different positions of F4356.55 is caused by a small 
shift of the benzene rings in the two ligands. The benzene ring on cetirizine is closer 
to helix VI by about half an angstrom, and it is almost perpendicular to the F4356.55 
benzene ring, forming a perfect face-to-edge interaction, while the counterpart 
F4356.55 benzene ring in H1-doxepin complex just forms hydrophobic interaction with 
the edge of the tricyclic moiety on doxepin. Doxepin contacts with Y108 via face-to-
edge interaction instead. Although in the H1-cetririzine complex the residue Y108 
remains at the same position as in H1-doxepin complex, benzene ring on cetirizine 
can only form hydrophobic contact with it. 
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Figure 2.21 Electron densities for F4356.55 and benzene ring of cetirizine in 
structure of H1-cetirizine complex are well defined.  
Figure 2.22 Interaction of F4356.55 with doxepin vs. Cetirizine. Cetirizine is shown as orange sticks, 
doxepin is shown in green sticks. F4356.55 and Y1083.33 are shown in the matching colours with the 
interaction ligands. Cartoon representation of H1 receptor structure.  
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This difference can illustrate that small variations on the ligand structure could lead to 
a different way of binding, and might lead to changes on protein conformation.  
2.2.6.3  Interactions between fexofenadine and the H1 receptor 
Fexofenadine is another second-generation antihistamine, with the most extended 
structure. It contains some very similar moieties to cetirizine, including a 
diphenylmethyl moiety, a piperidine ring, a flexible alkyl chain and a carboxyl group 
(Fig. 2.23). The main structure difference between these two ligands is that 
fexofenadine has a very extended structure, with a benzene ring connected to the 
isobutyric acid moiety in place of the carboxylic acid group in cetirizine. A part of 
fexofenadine, from its diphenyl end to the amine moiety in piperidine ring inherited 
the binding mode of its counterpart in cetirizine, which sits deeply and firmly in the 
“lipophilic subsite”, and anchored tightly with residue D1073.32. While the rest part of 
the ligand structurally is longer, and binds to the receptor with some different 
interactions. 
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The superimposition of the two complexes (Fig. 2.23) presents that the two ligands 
almost overlapped at the diphenyl group. The diphenyl moiety of fexofenadine also 
adopts a butterfly-shaped conformation in the crystal structure, and it interacts with 
H1 within this “lipophilic subsite” in almost the same way with cetirizine: majority 
interactions are hydrophobic contacts. The piperidine ring of fexofenadine almost 
overlays on the piperazine ring of cetirizine, the amine moiety binds to D1073.32 
through salt bridge at the same position (Fig. 2.24). 
At the top of the binding site, the carboxyl group extended further towards helix VI, 
forms salt bridge with Lys450. The benzene ring that attached to the isobutyric acid 
oriented perpendicularly to H450 and forms a π-stacking interaction, the benzene ring 
Figure 2.23 Superimposition of cetirizine and fexofenadine. Cetirizine is shown as orange 
sticks, fexofenadine is shown as pink sticks. Cartoon representation of H1 receptor structure.  	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also forms hydrophobic interactions with K179. These binding features ensure that 
fexofenadine bind more specifically to H1.	   
Figure 2.24 Fexofenadine binding pocket. a. Direct view on polar contacts with the receptor; b. 
direct view on the “lipophilic subsite”.	  Fexofenadine is shown as salmon sticks, H1 receptor is 
shown as cartoon presentation, residue side chains are shown as yellow sticks, polar contacts are 
shown as red dash lines. 
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2.2.7    Radiolabelled ligand binding assays and Molecular Dynamics 
simulations 	  
The crystal structures of H1 complexes reported in this thesis for the first time 
revealed the interactions between H1 and second-generation antihistamines. The 
specific binding mainly focuses at the “anion binding site”, including residues K179, 
K191 and H450.  
 
However, the two lysines do not have any electron density as mentioned previously, 
their positions and conformations are not defined confidently. In order to explore their 
roles in binding, mutagenesis around these residues has been carried out and 5 
mutants were produced. The binding affinities of these mutants obtained from 
radiolabeled ligand binding assays are shown in Table 2.6. 
 
There was no big variation observed among mutants or between different pH systems 
(pH7.5 and pH5.8) for the KD values to [3H]-pyrilamine, all in the range of 1-10 nM. 
Most of the mutations did not show significant influence on Bmax values at both pHs, 
except the triple mutant (K179A+K191A+H450). The Bmax value of this mutant 
dropped more than four-fold compare to the wild type at both pHs. The possible 
reason for it is that mutating all three residues at the same region to alanine 
simultaneously could cause non-direct effects to the protein stability and function. 
This mutant might be not very stable or the binding efficiency has decreased 
significantly. 
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For Ki values at pH7.5, mutant K191A has an obvious large value for cetirizine, 
which is 731 nM, while the value for wild type is 140 nM. This difference 
corresponds with other literatures. The double and triple mutants both include the 
K191A mutation, and reduced affinities were also observed for them. No significant 
difference was observed for fexofenadine. It might be due to fexofenadine having a 
very long and chunky moiety at the extracellular side of the binding site, which 
enabled the ligand has more interactions with the protein; while for cetirizine, the 
interaction with residue K191 has a more important role in binding. 
 
Since the overall variations in affinity among the mutants are quite small, over 
interpretation should be avoided. However, the obvious difference is the values 
between different pHs. The crystallization condition was at acidic pHs, and the human 
tissue where inflammation normally takes place also has a local acidic environment. 
Therefore, the binding assays were also performed at pH5.8. As described in early 
section, at pH5.8, more proportion of amine moiety on the ligands is protonated, 
which should improve the affinity of the ligands in theory. And the binding assay 
results have proved that indeed binding affinity of all the mutants are much higher at 
pH5.8 than at pH7.5 for cetirizine and fexofenadine, around 10 times and 3 times 
higher respectively. The observed decreased Ki values for the H191A containing 
mutants at pH7.5 were not observed at pH5.8. This could be because of the overall 
much higher affinities have overwritten the mild differences triggered by H450A. 	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At	  pH7.5	  	  
	   	   	   	   	   	  H1-­‐PYRILAMINE	  
	   	   	   	   	  Mutant	   KD	  (nM)	   pKD	   Bmax	  
	   	   	  K179A	   7.29	   8.14	   18.55	  
	   	   	  K191A	   6.18	   8.21	   24.18	  
	   	   	  H450A	   8.08	   8.09	   10.46	  
	   	   	  K+K	   3.38	   8.47	   10.16	  
	   	   	  K+K+H	   2.84	   8.55	   3.27	  
	   	   	  WT	   8.21	   8.09	   14.67	  
	   	   	  
	   	   	   	   	   	   	  H1-­‐CETIRIZINE	  
	   	  
H1-­‐FEXOFENADINE	  
	  Mutant	   Ki	  (nM)	   pKi	   	  	   Mutant	   Ki	  (nM)	   pKi	  
K179A	   103	   7.02	  
	  
K179A	   141	   6.86	  
K191A	   731	   6.21	  
	  
K191A	   84	   7.08	  
H450A	   158	   6.84	  
	  
H450A	   202	   6.73	  
K+K	   641	   6.22	  
	  
K+K	   160	   6.81	  
K+K+H	   745	   6.17	  
	  
K+K+H	   266	   6.62	  
WT	   140	   6.86	  
	  
WT	   130	   6.89	  
	   	   	   	   	   	   	  At	  pH5.8	  	  
	   	   	   	   	   	  H1-­‐PYRILAMINE	  
	   	   	   	   	  Mutant	   KD	  (nM)	   pKD	   Bmax	  
	   	   	  K179A	   3.00	   8.60	   18.80	  
	   	   	  K191A	   3.15	   8.54	   18.88	  
	   	   	  H450A	   2.26	   8.69	   9.67	  
	   	   	  K+K	   2.77	   8.58	   14.53	  
	   	   	  K+K+H	   1.64	   8.81	   4.73	  
	   	   	  WT	   4.22	   8.43	   19.20	  
	   	   	  
	   	   	   	   	   	   	  H1-­‐CETIRIZINE	  
	   	  
H1-­‐FEXOFENADINE	  
	  Mutant	   Ki	  (nM)	   pKi	   	  	   Mutant	   Ki	  (nM)	   pKi	  
K179A	   11.70	   7.93	  
	  
K179A	   33.28	   7.43	  
K191A	   16.83	   7.78	  
	  
K191A	   31.12	   7.46	  
H450A	   4.63	   8.35	  
	  
H450A	   17.07	   7.74	  
K+K	   23.27	   7.64	  
	  
K+K	   55.77	   7.24	  
K+K+H	   38.22	   7.43	  
	  
K+K+H	   35.89	   7.28	  
WT	   16.01	   7.80	  
	  
WT	   47.84	   7.18	  	  
 
 
Table 2.6 KD Ki and Bmax values obtained from RLB assays at pH7.5 and 
pH5.8 for 5 different H1 mutants plus a wild type H1. 
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However, with the data of radiolabelled ligand binding assays, it is still not clear 
about the roles of the three residues. In order to explain the data, molecular dynamics 
(MD) simulations on the crystal structure of H1 bound to cetirizine were carried out 
by our collaborator Mr. Benjamin Morris from Biggin’s Group, University of Oxford. 
From the results of the MD simulations, how these interactions varied over the course 
of the MD simulations were observed, the data is summarized in Table 2.7. It is clear 
from SD simulations results that the three residues in the mutagenesis do not form 
constant interactions with the cetirizine.  
 
The comparison between these results and the frequency of interactions between other 
parts of the ligand, and different binding site residues (Table 2.7), indicating that the 
interactions between aromatic residues and the aromatic parts of the ligand form very 
stable interactions.  
 
 
 
 
Table 2.7 Interactions between the nearest sidechain nitrogen atom, and oxygen 
atoms of cetirizine. Where O1 and O2 are the oxygen atoms of the carboxylic acid 
group, and O3 is the ether. 
 Time spent under 4Å distance (%) 
Residue 1 Residue 2 MD run 1 MD run 2 MD run 3 Total 
K179 Cetirizine 
(O1/O2) 
22 24 45 30 
K179 Cetirizine (O3) 64 3 3 23 
K191 Cetirizine 
(O1/O2) 
4 17 0 7 
H450 Cetirizine 
(O1/O2) 
45 28 56 43 
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Table 2.8 Interactions between the nearest protein sidechain atom to atoms of 
cetirizine. A π-stacking interaction is defined as the ligand and sidechain being 
within 5.5Å and a hydrogen bond is defined as being within 4Å. Here, N2 is nitrogen 
atom at the end of the piperazine nearest the ether. 
 
Residue 1 Residue 2 Time spent interacting (%) 
Y108 Cetirizine (ring 1) 91 
F109 Cetirizine (ring 2) 95 
D107 Cetirizine (N2) 61 
W158 Cetirizine (ring 1) 59 
 
  
  
  
  
  
  
  
  
Figure 2.25 Cetirizine (left) and Pyrilamine (right). 
 
It is clear from Tables 2.7 and 2.8 that the key interactions with cetirizine are the 
interactions lower in the pocket: these interactions have a much higher frequency than 
any of the interactions with K179, K191, or H450. The percentage contribution of the 
binding energy is likely much higher for the deep pocket residues than for the charged 
residues in the mutagenesis data. It is important to note that the ether and carboxylic 
acid groups of cetirizine are the part of the scaffold that differs from that of 
pyrilamine (Fig. 2.25), which was used in the binding assays for cetirizine and 
fexofenadine to compete against. That is to say that pyrilamine likely doesn't form 
interactions with K179, K191, or H450; or at least it can't form salt bridges or 
hydrogen bonds with them. 
 
The residues in the mutagenesis are all large and on top of the binding pocket, this 
coupled with the fact that they likely don't have a large contribution to binding free 
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energy, leads us to believe that they could instead contribute mainly to binding 
kinetics. Mutating these residues to alanine could result in a small reduction in 
binding energy, but a big change in the on or off rates of large ligands such as 
cetirizine. The effect on binding kinetics would likely be different for smaller ligands 
such as pyrilamine, so competition assays would be clouded. 	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2.3   Discussions 
Previously, the only crystal structure of H1 was in a complex with doxepin, 
determined at 3.1 Å (Shimamura et al., 2011). With this single structure of H1, the 
global impacts of other ligands on the overall protein structure or local impacts on the 
ligand-binding site are not well understood. Since doxepin is a small ligand and it 
binds quite deeply, the binding mode of entry area of the binding pocket is not known. 
Although one structure is sufficient for the docking of some ligands, challenges still 
remain for more ligands. Firstly, when docking with different ligands, it is hard to 
estimate the degree of conformational changes of the ligand-binding pocket. 
Secondly, the binding pocket is quite large, which means there are more than one 
binding models that could be produced by the docking software, with similar scores. 
The two extra crystals structures of H1-ligand complexes described in this thesis 
could be potentially valuable for further improvement on in-silico docking or new 
drug discovery. Structures have provided further details of ligand binding, which 
could potentially assist with better analysis of the range of conformational changes 
different ligand could trigger. 
The small structural differences observed between the three complexes demonstrate 
that different ligands have minor effect on the structure of the receptor. The 
“lipophilic subsite” and the “D1073.32 ionic interaction region” of the binding pocket 
are highly conserved. Therefore, they are not expected to relate with any selectivity 
functions on protein subtypes or advanced pharmacological properties (eg. BBB 
permeability, solubility and metabolism). Their roles are more associated with the 
tight binding of the ligands. The conformational changes are very small, beyond the 
resolutions of the X-ray data in this study. 
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Cetirizine and fexofenadine are both second-generation antihistamines. Previous 
docking studies using the H1-doxepin structure as a model suggested that they could 
both bind specifically to H1, via the “anion binding site” (Shimamura et al., 2011). 
The structures reported here well correspond with the predicted ligand binding modes, 
confirmed the residue H4507.35 is indeed forming salt bridges with both ligands. 
However, the conformation of the rest part of the “anion binding site” including the 
K179ECL2 and K1915.39 could not be modeled accurately in all three complexes. 
Therefore, the specific binding mode with these residues could not be identified. In 
order to define their roles in binding, a series of radiolabelled ligand binding assays 
were designed and carried out for five H1 mutants with key residues at the “anion 
binding site” mutated to alanines. The results were not as expected, there was no 
obvious decrease in affinities of the mutants with the key residues mutated to 
alanines. Possible explanation would be that residues at the “anion binding site” are 
not associated with binding affinity as expected, but more related to binding 
specificities. To interpret these data, the MD simulation studies were carried out by 
our collaborator on cetirizine, the results suggested that, second generation ligands 
might have minor effect on the protein structure changes and ligand affinities, but 
significantly larger impact on receptor dynamics. 
Thank to crystallography, we get to understand more about GPCRs in the recent 
years. However, protein crystals normally trap molecules in their low energy 
conformations, which only present part of the signaling process. Now we start to 
realize that GPCR dynamics play very important role in their functions and can 
explain their complicated signaling behaviors. GPCR dynamics involves energetics in 
different conformational states and the transition between these states. They are the 
direct cause to ligand binding efficiency and downstream responses for many GPCRs. 
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To address this problem, molecular dynamics simulations and more biophysical 
studies, such as NMR and time-dependent derivatization with chemical probes should 
be carried out as complementary methods. 
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3  Chapter Three 
 
Screening of Constructs and 
Development of Expression Protocols 
of the Histamine Receptor H3 for 
The Purpose of Structural Studies 
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3.1   Overview  
For membrane structural studies, obtaining well-ordered diffraction-quality crystals is 
quite challenging. It requires a sufficient quantity of protein with a good level of 
homogeneity and stability. Therefore, it is necessary to have a rapid and reliable 
screening strategy to produce the most suitable constructs and a suitable expression 
system for protein production prior to crystallization trials. Here, 47 different 
|Histamine receptor H3 (H3) constructs were screened by a high throughput protein 
expression screening platform. Further optimization was carried out by inspecting 
protein homogeneity using fluorescence-detection size-exclusion chromatography 
(FSEC). Satisfactory results were obtained as the optimal expression factors in insect 
cells were identified for the best construct (G4). Large-scale expression and 
purification of H3 was attempted. While expression was achieved, future work (eg. 
purification and crystallization) need to be carried out in presence of the antagonist. 
3.2   Materials and Methods 
3.2.1   High throughput expression screening with different 
expression systems 
The initial high throughput protein expression screens were carried out at OPPF-UK 
(Oxford Protein Production Facility, Research Complex at Harwell).	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3.2.1.1  Construct design and synthesis 
Twelve constructs were designed based on full-length sequences of H3 from both 
human and turkey with different T4 Lysozyme insertion sites on ICL3. All constructs 
studied were synthesized by GenScript. These twelve constructs were used as 
templates, and 47 further constructs with various truncations at the N- and C- termini 
were designed and generated using Clontech In-Fusion cloning system according to 
the manual. The different H3 constructs were amplified by PCR and subcloned into 
vector pOPINE-3C-eGFP, which was developed by OPPF for multi-host expression 
and allows expression in bacterial, mammalian and insect cell lines (Berrow et al., 
2009). It has a GFP tag and a hexa-histidine tag at the C terminus, with a 3C 
proteolytic cleavage site between the target sequence and GFP. GFP works as a 
reporter for monitoring protein expression systems since it emits a strong fluorescence 
signal.  
 
3.2.1.2  Small-scale expression screening 
pOPINE-3C-eGFP-his
6265 bp
AmpR
CMV  Enhancer
eGFP-­H is
3C   cleavage  site
Rabb it  ß -­Globin   Po ly  A  Site
Ch icken   ß -­Actin   Promoter
p10  Promoter+5'UTR
T7  Promoter
lac  Operator
pUC  orig in   o f  rep lication
T7  Terminator
lef2/ORF  603
ORF  1629
AvaI (19 52)
ClaI (3557)
NcoI (2332)
PmeI (2709)
ApaLI (49 96)
ApaLI (6084)
Figure	  3.1	  pOPINE-­‐‑3C-­‐‑eGFP	  vector	  (Addgene	  plasmid	  #	  41125)	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3.2.1.2.1  E.coli expression screening 
H3 plasmids were transformed into 3 different competent cell lines: C41, BL21Lemo 
and C43. Positive single transformants were picked from LB agar plates 
supplemented with carbenicillin, and were used for inoculating 0.7 ml cell cultures  
using Power Broth medium supplemented with carbenicillin in 96 deep well blocks 
(ABgene AB-0932), sealed with gas-permeable adhesive seal (ABgene AB-0718).  
The filled deep well blocks were put into a shaking incubator at 37°C, 225 rpm 
overnight. The overnight cultures were diluted by adding 15 µl of overnight cultures 
to 3 ml of TB medium (auto-induction medium) and Power Broth medium 
supplemented with carbenicillin in 24 deep well plates. The cells were grown in a 
shaking incubator at 37°C, 225 rpm for 3-5 hours, until the OD600 was around 0.5, the 
cells were induced by adding IPTG to a final concentration of 1mM. Growth was 
continued for 18 hours at 20°C, 600 rpm. The cells were harvested by centrifugation 
at 2000g for 10 minutes, and then frozen at -80 °C for further characterization. 
3.2.1.2.2  Mammalian cells (HEK 293) expression screening 
HEK293 (Human Embryonic Kidney) cell stock (provided by OPPF-UK) was grown 
to the concentration of 1.5-2 x 105 cells/ml.  The cells were transferred into 24 well 
plates, 1 ml per well. The plates were incubated at 37 °C overnight under a 5% CO2 / 
95% air atmosphere. The medium was removed from the cell layer by aspiration, and 
then 1 ml of DMEM medium supplemented with 2% FCS (foetal calf serum) added to 
each well. The cells were transfected by adding 1 µg plasmid DNA of each construct 
and 44 µg GeneJuice cocktail (Merck) to the cells and incubated at 37 °C for 3 days 
under a 5% CO2 / 95% air atmosphere. The GFP expression level was inspected by 
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fluorescence microscopy at this point, the supernatant was discarded and cell pellets 
of all constructs were frozen at -80°C for further characterization. 
3.2.1.2.3  Insect cells (baculovirus) expression screening 
The insect cells Spodoptera frugiperda (Sf9) (provided by OPPF) was propated in 
Sf900II medium (Invitrogen) as suspension culture, in 100-500 ml volumes with a 
medium/flask volume ratio of 1/5 at 26°C. The cells were passaged to a density of 
4x105 cells/ml every 3-4 days. The virus production and small-scale expression 
screening were carried out in monolayer and suspension cultures respectively.  
 
To produce the initial virus stock (P0 virus), the Sf9 cells were grown to a density of 
5x105 cells/ml in Sf900II medium prior to infection. Then Sf9 cells were transferred 
into two 24 well plates (500 µl per well) and left to attach for 30 minutes at room 
temperature. Cells were transfected by adding transfection mix (250 ng of bacmid, 
100-500 ng of vector DNA, 50 µl of Sf900II medium and 1.5 µl of FugeneHD 
transfection reagent (Promega)) into each well, followed by a gentle swirl, and 
incubation for 5-6 days at 26°C. The supernatant was harvested without touching the 
cell monolayer to create the P0 virus. 
 
To amplify the virus, the Sf9 cells in Sf900II medium were prepared at a 
concentration of 1x106 cells/ml before use. The Sf9 cells were transferred into two 24 
well plates, 500 µl per well and left for 30 minutes at room temperature. 5 µl P0 virus 
stock was added to cells in matching format, and the cells incubated for 6 days at 
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26°C. The supernatant was harvested to create the second passage virus stock (P1 
virus). 
 
For the small-scale expression test, the Sf9 cells in Sf900II medium were prepared at 
concentration of 1x106 cells/ml before use. The Sf9 cells were transferred into 24 well 
plates with 5 ml per well. 5 or 50 µl of P1 virus was added to each well and the cells 
incubated at 26°C with shaking at 120 rpm. 1ml of culture was harvested using 96 
well plates after 72 and 96 hours by centrifugation for 15 minutes at 2000g, 
supernatant was removed and cell pellets were frozen and stored at -80°C for further 
characterization. 
3.2.1.3  Small-scale membrane solubilisation 
Cell pellets of three cell lines were disrupted by freezing at -80°C for 1 hour, 
defrosting for 20 minutes, then re-suspending in 200 µl of NPI-10 buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole and 1% Tween 20, pH 8), supplemented 
with 1 mg/ml lysozyme, protease inhibitor and DNAse I. The cells were shaken at 800 
rpm at 4°C for 30 minutes, 1% of DDM and 0.2% CHS was added to the suspension, 
which was shaken for another 2 hours, followed by ultra-centrifugation at 55k g for 
15 minutes. The supernatants were collected by gentle aspiration and crude membrane 
samples were analyzed by SDS-PAGE gel and/or FSEC. 
3.2.1.4  Fluorescence-Detection Size-Exclusion Chromatography 
(FSEC) 
The FSEC system includes a SEC column (Superose 6 10/300 GL) connected to a 
fluorescence detector to detect the GFP fusion protein during elution. This system is 
suitable to analyse crude membranes and little protein is required. 
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The expression level and monodispersity of protein in solubilized membranes  from 
different constructs were screened by FSEC. The column was equilibrated with buffer 
containing 0.03% DDM, 0.006% CHS, 20 mM Tris (pH7.5) and 150 mM NaCl and 
100 µl of each solubilized membrane sample was applied onto the SEC column 
attached to a Shimadzu High Performance Liquid Chromatography System. The 
column was ran with a flow rate of 0.3 ml /min and GFP fluorescence monitored by 
excitation of 488 nm and emission of 512 nm. 
3.2.2   Expression optimization with insect cell/baculovirus system 
Many factors could affect the protein expression level and quality in baculovirus 
system, including cell line, medium, oxygen supply, bioreactor size/shape, infection 
strategy and harvesting time. Infection strategy is normally the first factor to be 
optimized for a new recombinant protein of interest. The analyzed samples were 
crude membranes, using GFP fluorescent signal to monitor and compare the 
production of each target fusion protein. The effects of different factors on the 
expression of recombinant protein were evaluated in two aspects: protein yield and 
protein quality by SDS gel or FSEC profiles.  
3.2.2.1  Optimization of MOI, TOI and HT for H3 construct C6 and 
G4. 
Initially, the infection strategy was optimized around the multiplicity of infection 
(MOI), time of infection (TOI), and the time of harvesting. MOI refers to the different 
passages/titers/quantities of the viruses, TOI refers to the measured cell density at the 
time of infection, and time of harvesting refers to the time post infection for cell 
harvesting. 
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For this series of optimization, factors under optimization are listed below: 
•   Construct: Histamine receptor H3, construct C6 and G4 (Table 3.1). 
•   TOI: 1x106 and 2x106 cells/ml . 
•   MOI: Virus passage: P1 and P2; Virus volume: 1, 5, 10 ul of virus in 5 ml of cell 
cultures. 
•   Time of harvesting: 48 and 72 hours post infection. 
•   Cell line: Sf9, Sf21 and Hi5. 
3.2.2.1.1  Optimization on MOI: different virus passages 
Stock viruses of four H3 constructs (C6, G4, F5 and G6 as shown in Table 3.1) were 
chosen to compare the P1 and P2 virus stock in order to get a general idea of virus 
quality. The rest of the tests were performed with constructs C6 and G4. P2 virus 
(generated after a third passage) was amplified from second passage as described for 
the P1 virus. For H3 protein expression, 5 ml of Sf9 suspension culture were infected 
at TOI of 1x106 cells/ml, with 5ul of P1 and P2 viruses and harvested at 72 hours post 
infection. Cell pellets were solubilized and analyzed by SDS-PAGE gel (in-gel 
fluorescence).  
3.2.2.1.2  Optimization on TOI, MOI and time of harvesting 
The tests to investigate the factors of TOI and time of harvesting were carried out 
sequentially, while each of them was done by orthogonal experiments with MOI (1-10 
quantitatively). 5 ml of Sf9 suspension culture were infected at TOI of 1x106 and 
2x106 cells/ml, with 1-10 ul of P1 viruses and harvested at 48 and 72 hours post 
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infection. Cells were harvested and solubilized as described before. The crude 
membranes were analyzed by the FSEC system. 
3.2.2.2  Optimization on cell lines with a better control of virus titer 
P2 virus titer was estimated based on the changes on diameters of viable cells, in 
order to have a better control of virus titer. Further optimization was performed for 
construct G4 on 3 different cell lines: Sf9, Sf21 and Hi5. 
3.2.2.2.1  P2 virus amplification and titer estimation based on 
increased cell diameter following infection 
10ml of Sf21 cells in flasks were infected with 5 µl of P1 viruses when the cell 
density was around 1x106 cells/ml, with the viability (above 95%), the cell diameter 
were measured and recorded. 85 hours post infection, the cell density, viability and 
cell diameter were measured and recorded. The virus titer was calculated based on the 
change on the size of cells, which will be described in details in results section. The 
viruses were collected by a slow spin at 800g for 5 minutes. The P2 virus stock was 
made to the final concentration of around 5x109 virus particles/ml by resuspending the 
cell pellet with freezing mix (DMSO 10%, media, serum FBS 10%). and aliquoting 
into 2ml tubes before storing at -80C. 
3.2.2.2.2  Cell line optimization 
The expression test was performed in three cell lines: Sf21, Sf9 and Hi5, with the TOI 
of 1x106 cells/ml. The tests were performed by orthogonal experiments with the MOI 
of 1, 5 and 10, and harvesting time of 48 hours and 70 hours post infection. 3ml of 
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cell culture (Sf9 and Sf21 in Sf900II medium, Hi 5 in Express Five medium, 
Invitrogen) was infected with P2 virus stock. The cell parameters before infection and 
before harvesting were monitored. Cells were harvested and solubilized as described 
before. The crude membranes were analyzed by the FSEC system. 
 
3.2.3   Large-scale expression 
 
Following the determination of the optimal factors for expression in insect cells, 
large-scale expression of H3 (G4 construct) was attempted. 5 Liters of Sf9 cell 
suspension in Sf900II medium were grown in a CellBag bioreactor-10L (GE 
Healthcare). The bioreactor was placed on a rocker platform, which was heated to 
27°C, with the rocking speed of 25 rpm at an angle of 7° from horizontal. Infection 
took place when the cell density of 1 x 106 cells/ml was achieved using 10 ml of P2 
recombinant virus. The bioreactor was kept inflated by an air pump with a flow rate of 
0.2 liters per minute to maintain bag pressure and oxygen for cell respiration. The 
cells were harvested at 70 hours post infection by centrifugation for 15 minutes at 
2000g. 
3.2.4   Purification of turkey H3 for the purpose of obtaining H3-T4L-
GFP fusion protein 
The purification of turkey H3 was attempted by adapting the purification protocols 
used for human H1. The main difference was all the steps are performed in the 
absence of any antagonist. Another difference was the method for cell disruption as 
the insect cells are much softer than yeast cells.  
 
The insect cell pellet was re-suspended in ice-cold breaking buffer containing 50mM 
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HEPES pH7.5, 120mM NaCl, 5% (v/v) glycerol, 2mM EDTA and EDTA-free 
protease inhibitor cocktail tablets, by stirring at 4 °C. The cells were then disrupted 
and washed by the method of dounce homogenation (20 strokes), ultracentrifugation 
and re-suspension. The wash was carried out with low salt buffer (10mM HEPES 
pH7.5, 5% (v/v) glycerol, 2mM EDTA and EDTA-free protease inhibitor cocktail 
tablets) first, and then repeated twice with the addition of 1M NaCl, 10 mM MgCl2, 
and 20mM KCl to the buffer. The membranes were collected by ultracentrifugation at 
100,000g for 45 minutes at 4°C. The concentration of whole membrane proteins was 
estimated using the bicinchoninic acid method (Pierce). The membrane suspension 
was solubilized by with 1% of DDM, 0.2% of CHS, and the addition of 2mg/ml 
iodoacetamide, for 1-2 hours, as described in the protocols for H1 in Chapter 2. After 
the solubilization step, the insolubilized materials were removed by 
ultracentrifugation. The supernatant was brought to IMAC step using TALON resin in 
the buffer containing 20mM HEPES pH7.5, 500mM NaCl, 10% glycerol, 0.025% of 
DDM, 0.05% of CHS. The fusion protein was eluted using 200 mM imidazole. All the 
fractions were checked by SDS–PAGE gel, and those containing H3-T4L-GFP pooled 
and concentrated to 2.5 ml. A small portion of the H3-T4L-GFP samples were mixed 
and incubated with 3C protease for cleavage to test the cleavage efficiency. The 
samples were assessed by SDS–PAGE gel. 
3.3   Results  
3.3.1   H3 Constructs   
The aim of this work was to find a construct/constructs that could lead to high 
expression levels, establish a suitable expression system and develop the optimal 
protocol that could produce good quality of the H3 protein in a sufficient quantity for 
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the purpose of structure determination. In order to achieve this, several recombinant 
genes containing H3-T4L with different T4L insertion positions were designed. These 
H3-T4L genes were later used as templates for making further constructs with various 
N- and C- terminal truncations. A total number of 47 H3-T4L constructs, together 
with an eGFP control were formatted into a 96 well plate and numbered accordingly 
(Fig. 3.2 and Table 3.1), they are used for expression host screening.  
 
 
 
 
 
 
 
 
 
 
 
	  
Figure	  3.2	  Snake-­‐‑plot	  of	  H3	  human	  transmembrane	  region	  with	  ICL3	  and	  Helix	  VIII.	  	  Red	  circles	  mark	  the	  most	  conserved	  residues	  within	  each	  TM.	  H3	  constructs	  were	  designed	  to	  have	  fusion	  body	  T4	  Lysozyme	  replacing	  most	  of	  the	  region	  on	  ICL3.	  The	  various	  insertion	  sites	  are	  shown	  as	  1,	  2,	  and	  3	  on	  TM	  5	  side	  and	  a,	  b,	  c	  on	  TM	  6	  side.	  The	  insertion	  sites	  on	  H3	  turkey	  are	  at	  the	  equivalent	  positions.	  Plot	  was	  generated	  by	  GPCR-­‐‑SSFE	  server	  (Worth	  et	  al.,	  
2011)	  
Helix  VIII  	  
            TM  I                                    TM  II                                      TM  III                                      TM  IV                              TM  V                                TMVI                                      TMVII  	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Construct number Template T4L insertion site N- truncation C- truncation 
A1 Human T4 window 1 3c 22 476 
B1 Human T4 window 1 3c 27 476 
C1 Human T4 window 2 2c 22 475 
D1 Human T4 window 2 2c 27 475 
E1 Human T4 window 3 3b 22 475 
F1 Human T4 window 3 3b 27 475 
G1 Human T4 window 4 2b 22 474 
H1 Human T4 window 4 2b 27 474 
A2 Human T4 window 5 1a 22 472 
B2 Human T4 window 5 1a 27 472 
C2 Human T4 window 6 3a 46 494 
D2 Human T4 window 6 3a 51 494 
E2 Human T4 window 6 3a 1 494 
F2 Human WT -- 1 445 
G2 Turkey T4 window 1 3c 47 508 
H2 Turkey T4 window 1 3c 47 513 
A3 Turkey T4 window 1 3c 53 508 
B3 Turkey T4 window 1 3c 53 513 
C3 Turkey T4 window 1 3c 59 508 
D3 Turkey T4 window 1 3c 59 513 
E3 Turkey T4 window 2 2c 47 507 
F3 Turkey T4 window 2 2c 47 512 
G3 Turkey T4 window 2 2c 53 507 
H3 Turkey T4 window 2 2c 53 512 
A4 Turkey T4 window 2 2c 59 507 
B4 Turkey T4 window 2 2c 59 512 
C4 Turkey T4 window 3 3b 47 507 
D4 Turkey T4 window 3 3b 47 512 
E4 Turkey T4 window 3 3b 53 507 
F4 Turkey T4 window 3 3b 53 512 
G4 Turkey T4 window 3 3b 59 507 
H4 Turkey T4 window 3 3b 59 512 
A5 Turkey T4 window 4 2b 47 506 
B5 Turkey T4 window 4 2b 47 511 
C5 Turkey T4 window 4 2b 53 506 
D5 Turkey T4 window 4 2b 53 511 
E5 Turkey T4 window 4 2b 59 506 
F5 Turkey T4 window 4 2b 59 511 
G5 Turkey T4 window 5 1a 47 504 
H5 Turkey T4 window 5 1a 47 509 
A6 Turkey T4 window 5 1a 53 504 
B6 Turkey T4 window 5 1a 53 509 
C6 Turkey T4 window 5 1a 59 504 
D6 Turkey T4 window 5 1a 59 509 
E6 Turkey WT -- 1 469 
F6 Turkey WT -- 37 469 
G6 Turkey WT -- 59 469 
H6 eGFP (control) -- -- -- 
 
 
Table	  3.1.	  List	  of	  H3	  constructs	  with	  different	  T4L	  insertions	  positions	  and	  various	  N-­‐‑	  
and	  C-­‐‑	  terminus	  truncations	  formatted	  into	  a	  96	  well	  plate	  and	  number	  accordingly.	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3.3.2   Small scale expression screening 
3.3.2.1  E.coli expression screening 
From the SDS-PAGE gel analysis, despite various cell strains and medium types 
having been tried, there was very little expression of H3-GFP fusion protein from 
E.coli system. This just confirmed that E.coli is a poor host for heterologous 
expression of H3, which might be expected, since eukaryotic proteins like GPCRs do 
not usually express well in E coli. I general, GPCRs do not express well in E.coli  as 
the composition of membrane is different, which is important to maintain the integrity 
of eukaryotic protein structures. This system has been often used for screening 
because of the low cost, and fast growth rate. However, in this study, because of the 
small-scale high throughput expression screening strategy, the cost and growing time 
became minor concerns. 
3.3.2.2  4.2.2.2 Mammalian expression screening 
 
Inspection of the HEK293 cells for expression levels 72 hours after transfection was 
performed using fluorescence microscopy. There was almost no expression of GFP 
for any construct except for the eGFP control (data not shown). This might be caused 
by an unhealthy cell stock. Mammalian cell expression is quite problematic, the cell 
lines health is critical for expression (Andrell and Tate, 2013). However, compared to 
other expression hosts, mammalian cells provide the most native-like environment for 
eukaryotic protein expression, (for example, lipid composition) and the method is 
believed to be an currently under-used system because of the high cost and difficulties 
in maintaining healthy cell lines (Andrell and Tate, 2013). However, it is worth 
putting more effort into the expression optimization if one tried other expression hosts 
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and still expects better homogenous protein yield. Such as for setting crystallization 
trials, minimum of 0.5-1 mg of pure concentrated protein is needed. 
3.3.2.3  Insect cells expression screening 
 
From the whole cell GFP expression level of 72 hours post infection (Fig. 3.3), turkey 
constructs expressed more than the human variants. It shows a similar expression 
pattern when different volumes of P1 virus were used, while infection with 5 µl per 5 
ml of culture of P1 virus gave slightly higher expression level than with 50 µl per 5 
ml of culture.  Extending the infection time to 96 hours  did not show much difference 
in the yield of H3 (data not shown). 
 
 
SDS-PAGE gel analysis illustrated in Figure. 3.4, shows the H3-GFP fusion proteins 
expressed well in insect cells. However, it was observed that large amounts of free 
GFP also were produced, which may result from adventitious proteolysis. The 
different amounts of P1 virus still gave similar results in terms of expression, while 
the infection time  present notably different results on the gel. Cells harvested 72 
Figure	   3.3	  GFP	   fluorescence	   3D	   image	   of	   insect	   cell	   pellets.	   Cells	   were	   harvested	   72	  hours	  post	  infection.	  Cell	  pellets	  in	  96	  well	  plate	  format.	  5	  μl	  P1	  virus	  expression	  in	  columns	  1-­‐‑6,	  and	  50	  μl	  P1	  virus	  expression	   in	   columns	  7-­‐‑12.	  Cell	  pellets	   in	  black	  circles	  presented	  better	  profiles	  on	  SDS-­‐‑PAGE	  gel.	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hours post infection show promising GFP-fusion protein bands, while cells harvested 
96 hours post infection display an increased amount of free GFP bands and almost no 
target protein. This probably because of the p10 promoter on pOPINE vector (Fig. 
3.1) is a late promoter, which only switches on about 24 hours after infection, the 
expression of target proteins driven by this promoter should start 48-72 hours after 
infection, and the virus cycle can cause cell death and lysis about 4-5 days post 
infection (Massotte, 2003). Therefore, 72 hours is the good time point that protein 
production has started long enough for post-translational modifications, but not too 
long causing cell death.  
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Figure	   3.4	   SDS-­‐‑PAGE	   gel	   analysis	   of	   H3	   insect	   cells	   expression	   screen.	   Solubilized	  crude	  membranes	  are	  from	  insect	  cells	  expression	  system,	  72	  hours	  post	  infection.	  5	  μl	  P1	  virus	  expression	  is	  A1-­‐‑H6,	  and	  50	  μl	  P1	  virus	  expression	  is	  A7-­‐‑H12.	  Gels	  were	  visualized	  by	  in-­‐‑gel	  fluorescence.	  Arrows	  indicate	  GFP	  fusion	  H3	  protein	  bands.	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3.3.2.4  Fluorescence-Detection Size-Exclusion Chromatography 
(FSEC)  
Solubilized membranes from insect cells with an infection time of 72 hours were 
further characterized using FSEC. The SEC profiles of most constructs present 
multiple, broad and asymmetric peaks, suggesting they were not stable in the 
detergent-containing buffer or incorrectly folded during expression. However, 9 
constructs out of 47 gave reasonable symmetric and sharp peaks, the retention time is 
indicating a H3-T4L monomer as shown in Figure 3.5, Interestingly, they are all 
turkey constructs, indicating that turkey H3 protein sequences are more prone to 
express with better folding and stability. 
 
 
Figure	  3.5	  FSEC	  profiles	  of	  best	  H3	  constructs.	  Crude	  membranes	  were	  from	  insect	  cells	  expression	  system,	  72	  hours	  post	  virus	  infection.	  H1	  profile	  indicates	  the	  correct	  elution	  time	  as	  a	  positive	  control.	  The	  arrows	  indicate	  the	  estimated	  positions	  of	  aggregate,	  H3	  monomer,	  and	  free	  GFP	  from	  left	  to	  right.	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Within the 9 constructs, the FSEC profiles of C6 and G4 shown very small 
aggregation peaks, indicating that the proteins of those constructs were quite stable 
and did not tend to aggregate. Comparison of the C6 SEC curve to a standard curve 
produced from the H1 membranes, suggests C6 could potentially yield 2 mg of target 
protein from 8 litres of culture, which is a sufficient yield for crystallization trials. 
Compared to C6 and G4, the SEC profiles of the other 7 constructs show much lower 
expression levels and the aggregation peaks are quite large. They might worth further 
optimization on expression conditions and detergents if C6 and G4 fail to yield 
crystals. Currently, constructs C6 and G4 represent the most suitable candidates to 
carry on to large-scale expression, purification and crystallization trials. It is worth 
keeping in mind that, FSEC was performed on diluted unpurified samples, while in 
crystallization trials, the purified protein is typically much more concentrated. 
Therefore, further work needs to be done to monitor the characteristics of these two 
constructs.  
 
From the initial screening work, the best expression system has been in insect cells, 
with an infection time of 72 hours. The constructs with the best bands on SDS-PAGE 
gel did not give nice FSEC profile, indicating in the insect cells expression system 
using pOPINE vector, whole cells expression level does not have much correlation 
with the usable yield of target protein (Fig. 3.4 and Fig. 3.5). The most promising 
constructs are C6 and G4, although they do not show the highest levels of GFP 
expression. The solublization buffers used during the screening work did not contain 
any antagonists, which are very important to improve protein stability by maintaining 
the receptors in their inactive state. During the proper protein purification procedures, 
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the antagonists should be added from solubilization step and through all the 
procedures afterwards, by which, in principle, should improve the protein stability and 
yield dramatically. 
 
3.3.3   Expression optimization with baculovirus system 
3.3.3.1  Optimization on MOI, TOI and time of harvesting for H3 
construct C6 and G4. 
3.3.3.1.1  Optimization on virus passages 
The expression level of each H3 construct was much higher when infected with P1 
virus than when  infected with P2 virus as shown by  SDS-PAGE  (Fig. 3.6). Several 
thick bands in the range between 23-41 kDa were observed from the P2 virus infected 
expression. They might be free GFP, GFP degradation products or GFP-peptide 
fragments. Although there was also a free GFP band observed for C6 construct 
infected with P1 virus, it can be easily to separated during the purification procedure. 
No bands were observed on the lane for G4 construct (P2 virus infected), which might 
due to mistakes in sample loading. However, the conclusion is that H3 expression 
level infected with P1 virus is better, and the factor of P1 virus was fixed during 
further optimization. 
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3.3.3.1.2  Optimization on MOI, TOI and time of harvesting 
In the FSEC profiles of TOI optimization, higher peaks of H3-GFP (construct C6) 
fusion protein have been observed for the TOI of 2x106 cells/ml (Fig. 3.7, Top panel), 
indicating a higher expression level. In terms of MOI, MOI of 1 has a strong influence 
on the expression level corresponding to the different TOIs, with a nearly doubled 
expression level at the high TOI, while MOI of 5 and 10 did not show significant 
differences. This result indicates that high TOI has the most significant influence on 
expression level when a low MOI is used. However, the peaks of the target protein are 
broader in the high TOI, and the free GFP and large aggregation peaks were also 
observed. 
 
On the other hand, the FSEC profiles of construct G4 presented some different results. 
The peaks of target protein were not significantly different between TOI of 2x106 
cells/ml and 1x106 cells/ml, but some large aggregation peaks have been observed at 
Figure	   3.6	   SDS-­‐‑PAGE	   gel	   analysis	   of	   H3	   insect	   cells	   expression	   using	   P1	   and	   P2	  
viruses.	  Solubilized	  crude	  membranes	  are	   from	  insect	  cells	  expressed	  with	  the	  P1	  and	  P2	  viruses	  of	  H3	  constructs	  (C6,	  G4,	  F5	  and	  G6).	  Gels	  were	  visualized	  by	  in-­‐‑gel	  fluorescence.	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the high TOI (Fig. 3.7, Bottom panel), indicating higher expression level of target 
protein might have been produced, but then turned to aggregation. For both 
constructs, the optimal MOI is 1. Therefore, the TOI of 1x106 cells/ml is fixed for 
following optimization.  
 
Optimization on time of harvesting of 48 and 72 hours post infection are compared in 
Figure 3.8. The FSEC profiles of the cells with late harvesting time have higher peaks 
for target protein for both constructs (C6 and G4). Harvesting time of 52 Hours post 
infection was also quickly checked (data not shown), and it turned up as a transition 
point in the increasing phase of expression level. 
Construct G4 always has a much smaller free GFP peak, the target protein peak is also 
sharper and more symmetrical than construct C6. From this point, G4 construct is 
used for further optimization. 
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Figure 3.7 FSEC profiles of H3 expression optimization on the factor of TOI. Comparison of 
crude membrane FSEC profiles between TOI of 1x106 cells/ml and 2x106 cells/ml. Top panel: H3 
construct C6. Bottom panel: H3 construct G4. 	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Figure 3.8 FSEC profiles of H3 expression optimization on the factor of Time of Harvesting. 
Comparison of crude membrane FSEC profiles between the harvesting time of 48 and 72 hours 
post infection. Top panel: H3 construct C6. Bottom panel: H3 construct G4. 	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3.3.3.2  Optimization on cell lines with a better control of virus titer. 
3.3.3.2.1  P2 virus amplification and titer estimation based on 
increased cell diameter following infection 
  
Table 3.2 Sf 21 cell parameters before and after infection 
Day 1: Sf21 cells before infection with P1 viruses C6 and G4 
 
Virus Cell density 
(cells/ml) 
Viability Cell diameter  
(µm) 
G4 1x106 97% 11.2 
C6 0.9x106 96% 11.1 
Day 5: 85 hours post infection 
 
Virus Cell density 
(cells/ml) 
Viability Cell diameter  
(µm) 
G4 3.6x106 96% 14.2 
C6 3.4x106 94% 13.6 
 
Previous viruses were produced by following a high through put pipeline at OPPF, the 
exact virus titer was not determined, and MOI was defined as volume of virus to 
volume of cells. In this section, P2 virus was amplified while cell parameters were 
monitored and the virus titers were estimated based on changes of cell diameters 
(Janakiraman et al., 2006) (Table 3.2). At the time of 85 hours post infection, the cell 
density has increased above 3 times and still with the viability of more than 90%, 
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indicating the cells are still in a good condition. Around 100 virus particles are 
produced per 1µm increasing in cell diameter. 
In the case of G4, cell diameter increased by 14.2-11.2=3µm, 300 virus particles were 
produced per cell. The virus concentration is 3.6x106x300=1.08x109 virus particles 
per 1ml of cell culture. 
In the case of C6, cell diameter increased by 13.6-11.1=2.5µm, 250 virus particles 
were produced per cell. The virus concentration is 3.4x106x250=0.85x109 virus 
particles per 1ml of cell culture. 
The P2 virus stock was made to the final concentration of around 5x109 virus 
particles/ml for the following tests. 
3.3.3.2.2  Optimization on three cell lines 
By knowing the exact titer of the P2 virus, a formula could be used to calculate the 
volume of virus needed for the MOI of 1, 5 and 10. The results are listed in Table 3.4. 
 
Where MOI=1, 5 and 10 
Virus concentration=5x109 virus particles/ml 
Table 3.3 Cell parameters before infection 
Cell line Cell density (cells/ml) Cell diameter  
(µm) 
Viability Note 
Sf21 1.7x106 10.3 98% Diluted to 1x106 
Sf9 1.2x106 10.6 92% -- 
Hi5 1.3x106 12.4 99% -- 
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Culture volume=3ml 
Here, Multiplicity of infection (MOI) refers to the plaque forming units (pfu) of virus 
used for infection / number of cells. 
In three cell lines, the cell parameters were measured and recorded in Table 3.5. At 48 
hours post infection, the cell densities of sf9 cell increased from 1.2 x106 cells/ml to 
2.5 x106 cells/ml at MOI=1, 3.3 x106 cells/ml at MOI=5 and 3.5 x106 cells/ml at 
MOI=10. This indicating that the cells were still growing after infection, the cell 
viability remained around 95%. At 70 hours post infection, cell densities at MOI of 5 
and 10 remained constant, while at MOI=1, the cell density increased from 2.5 
cells/ml to 2.9 cells/ml. These changes suggest that cells were all infected at 48 hours 
post infection for the MOI of 5 and 10, while for MOI of 1, a small part of the cells 
were not infected at 48 hours post infection, and were still able to divide further.  
Although a lower MOI result in a higher cell counts, the infection was not a 
synchronous infective process throughout the entire culture. The cell viabilities at 70 
hours post infection were all just under 90%, indicating the cell lysis just started. 
The cell densities of sf21 cell increased from 1 x106 cells/ml to around 1.3 x106 
cells/ml at all the MOIs at 48 hours post infection, indicating that the cells were still 
growing after infection, the cell viability was around 86% showing they have started 
breaking down. At 70 hours post infection, cell densities increased to around 1.7 x106 
cells/ml at all MOIs, suggesting a further cell growth. Cell viability at this point 
dropped to 64% and 72% for MOI of 5 and 10, respectively. This level of low cell 
viabilities is a sign that harvesting was a bit late. However, for the MOI of 1, the cell 
viability was still good, which is 90%. These data shows the infection did not spread  
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throughout the entire Sf21 cells cultures even after 48 hours post infection, regardless 
the MOIs were used. 
In the case of Hi5 cells, the cell densities increased from 1.3x106 cells/ml to 4 x106 
cells/ml at MOI=1, 3.1 x106 cells/ml at MOI=5 and 2.5 x106 cells/ml at MOI=10 at 48 
hours post infection, indicating that the cells remain growing after infection, the cell 
viability remained around 92% for MOI=1 showing they were in a very healthy states, 
Table 3.5 Cell parameters measured 48 and 70 hours post infection (construct G4) 
 
 48 hours post infection 70 hours post infection 
Cell 
line 
MOI Cell density 
(cells/ml) 
Viability Cell 
diameter  
(µm) 
Cell 
density 
(cells/ml) 
Viability Cell 
diameter  
(µm) 
Sf9 1 2.5x106 93% 13.4 2.9x106 82% 14.1 
5 3.3x106 95% 13.4 3.2x106 86% 13.5 
10 3.5x106 94% 13.7 3.5x106 72% 13.8 
Sf21 1 1.3x106 86% 14 1.6x106 90% 14.3 
5 1.3x106 86% 14 1.8x106 64% 13.3 
10 1.4x106 87% 13.4 1.8x106 72% 13.2 
Hi5 1 4x106 92% 16.4 3.4x106 73% 13.9 
5 3.1x106 72% 16.1 2.8x106 79% 12.2 
10 2.5x106 75% 15.3 2.3x106 66% 11.5 
Table 3.4 Volume of the virus used in the expression tests 
Cell line 
Volume of virus (µL) 
MOI 1 MOI 5 MOI 10 
Sf21 0.6 3 6 
Sf9 0.72 3.6 7.2 
Hi5 0.78 3.9 7.8 
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but below 75% for MOI of 5 and 10. A rapid cell lysis has occurred for both of them. 
All cell densities dropped at 70 hours post infection, as well as the cell viabilities have 
dropped below 80%. Indicating that all the cells have been infected, and Infected cells 
started lysis quite quickly.  
The expression level and protein quality from different cell lines was assessed by 
FSEC, as shown in Figure 3.9 and Figure 3.10. Cells harvested 48 hours post 
infection, expression levels were not high for Sf9 and Sf21 cell lines, the FSEC 
profiles for them are very similar, while for Hi5 cell line, the expression level is about 
three fold higher than the other two cell lines. However, a shoulder was observed on 
the left of protein peak. The protein quality is a downside from Hi5 cell line. 
 
Expression levels of Sf9 and Sf21 for cells harvested 70 hours post infection have 
increased, with Sf9 showing higher levels. The Aggregation and free GFP peaks are 
both small and the protein peak is relatively symmetric and sharp. The Hi5 protein 
peak is much smaller, with a huge free GFP peak, meaning most of the protein has 
degraded. Therefore, the optimal expression strategy for turkey H3 (construct G4) is 
Sf9 cell line, MOI of 10, TOI of 1x106 cells/ml, harvested at 70 hours post infection. 
This expression strategy could potentially yield 0.4mg fusion protein per liter of cell 
culture. 
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Figure 3.9 FSEC profiles of H3 expression optimization on cell lines. Comparison of crude 
membrane FSEC profiles between three cell lines: Sf9, Sf21 and Hi5.  
 
Figure 3.10 FSEC profiles of H3 expression optimization on cell lines. Comparison of crude 
membrane FSEC profiles between three cell lines: Sf9, Sf21 and Hi5.  	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3.3.4   Large-scale expression and one step IMAC purification of H3 
 
A large-scale expression was carried out with the optimal expression strategy 
developed from the earlier studies. A total amount of 48g of cell pellet was obtained 
from 5L of cultures grown in a CellBag bioreactor. Purification of H3 was attempted 
by one step IMAC to obtain H3-T4L-GFP fusion protein. The initial purpose was to 
check the protein yield from large-scale expression, and use the H3-T4L-GFP fusion 
protein to check its binding profiles to some ligands, and to screen a few H3 
antagonists for future purification and crystallization.  
 
SDS-PAGE analysis (Fig. 3.11) shows that the IMAC elution containing a  high yield 
of H3-T4L-GFP fusion protein, as well as large quantities of free GFP and other 
peptide fragments. A final quantity of 0.5 mg of H3-T4L-GFP fusion protein was 
obtained from 5L of cell cultures. Since this purification was a one-step IMAC 
purification, the poor purity of resultant protein was to be expected. However, the 
large fraction of free GFP also indicated that the H3 protein was not very stable 
through the purification steps, and further optimization of the purification was 
required, such as selecting the optimal detergent and lipid. Additionally, all the 
purification steps were carried out in the absence of antagonists, which potentially 
could be the main reason for the instability of the proteins. Cleavage of the GFP 
fusion with 3C protease was shown to occur with a high efficiency, and the cleavage 
product did not contain any fusion protein (Fig. 3.12). 
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Figure	   3.11	   SDS-­‐‑PAGE	   gel	   of	   H3-­‐‑T4L-­‐‑GFP	   fusion	   protein	   IMAC	   purification.	   Gel	   was	  visualized	  by	  Coomassie	  blue	  staining.	  	  
 
 
 
	  
Figure	   3.12	   SDS-­‐‑PAGE	   gel	   of	   H3-­‐‑T4L-­‐‑GFP	   fusion	   protein	   3C	   protease	   cleavage	   test.	   (left) 
Visualized by Coomassie blue staining and (right) visualized by in-gel fluorescence	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3.4   Discussions 
Briefly, through a series of screenings, the turkey H3 constructs are generally more 
stable than their human H3 counterparts. One possible reason for this could be that 
bird species have higher core temperature, and potentially   contain more 
thermostabllized genes. Sequence alignment of the human and turkey constructs 
(Appendix) shows that the two sequences have more than 90% identical residues at 
the inter-helical region, and have 100% identical residues at the conserved ligand 
contact positions. This demonstrates that the turkey H3 will be a good model for 
human H3 studies.  
The best expression system (insect cell) for turkey H3 has been established, and an  
optimal expression regime  identified. This expression system was tested many times 
in two different labs, showing this protocol is highly reproducible.  
Protein yield from the large-scale expression (0.1mg/L) was much lower than 
estimated from small-scale expression tests (0.4mg/ml). Attention should be drawn to 
changing bioreactor types and culture volumes. The dynamics of infection and protein 
expression are different between small flasks and large CellBags. The time to 
infection onset and optimal expression to happen might be different as well. The 
health condition of cells is harder to control in a CellBag. For secreted proteins, lysed 
cells are not a problem, while for membrane proteins, the healthy state of cells and 
membranes at the time of harvesting is critical. Also, expression in large CellBags   
requires more stringent controls on the cells environment, such as, a temperature-
controlled lab to mimic the incubator for small flasks to achieve optimal cell growth 
and protein expression. In spite of the reduced yield, H3-GFP fusion proteins have 
been successfully produced for functional studies and screenings of detergents and 
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antagonists, via techniques such as radioligand binding assays and Microscale 
thermophoresis. This expression protocol in insect cells could potentially lead to the 
production of milligram quantities of high quality H3 protein, for crystallization and 
structural determination. 
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Figure	  5.1	  Results	  from	  radioligand	  binding	  assays	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Figure 5.2 Sequence allignment of H3 human and Turkey. Conserved inter-helical contact positions 
are marked in red shade, conserved ligand contact positions are marked in green boxes. 	  	  
